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Interrogation of the human proteome in a highly multiplexed and efficient manner 
remains a coveted and challenging goal in biology.  We present a new aptamer-
based proteomic technology for biomarker discovery capable of simultaneously 
measuring thousands of proteins from small sample volumes (15 L of serum or 
plasma).  Our current assay allows us to measure ~800 proteins with very low 
limits of detection (1 pM average), 7 logs of overall dynamic range, and 5% 
average coefficient of variation.  This technology is enabled by a new generation of 
aptamers that contain chemically modified nucleotides, which greatly expand the 
physicochemical diversity of the large randomized nucleic acid libraries from 
which the aptamers are selected.  Proteins in complex matrices such as plasma are 
measured with a process that transforms a signature of protein concentrations into 
a corresponding DNA aptamer concentration signature, which is then quantified 
with a DNA microarray.  In essence, our assay takes advantage of the dual nature 
of aptamers as both folded binding entities with defined shapes and unique 
sequences recognizable by specific hybridization probes.  To demonstrate the 
utility of our proteomics biomarker discovery technology, we applied it to a clinical 
study of chronic kidney disease (CKD).  We identified two well known CKD 
biomarkers as well as an additional 58 potential CKD biomarkers.  These results 
demonstrate the potential utility of our technology to discover unique protein 
signatures characteristic of various disease states.  More generally, we describe a 
versatile and powerful tool that allows large-scale comparison of proteome profiles 
among discrete populations.  This unbiased and highly multiplexed search engine 
will enable the discovery of novel biomarkers in a manner that is unencumbered 
by our incomplete knowledge of biology, thereby helping to advance the next 
generation of evidence-based medicine. 
Proteins present in blood are an immediate measure of an individual’s phenotype 
and state of wellness.  Secreted proteins, released from diseased cells and surrounding 
tissues, contain important biological information with the potential to transform early 
diagnostic, prognostic, therapeutic, and even preventative decisions in medicine. 
We will realize the full power of proteomics only when we can measure and 
compare the proteomes of many individuals to identify biomarkers of human health and 
disease and track the blood-based proteome of an individual over time.  Because the 
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human proteome contains an estimated 20,000 proteins, plus post-translational variants, 
that span a concentration range of ~12 logs, there is great technical difficulty in 
identifying and quantifying valid biomarkers.  Proteomic measurements demand 
extreme sensitivity, specificity, dynamic range, and accurate quantification. 
The desire to profile the changes in protein expression at large scale is not new.  
Attempts at high-content proteomics began with 2-D gels and now mostly employ mass 
spectrometry (MS) and antibody-based technologies1.  MS can deliver specific 
analytical capabilities, but its sensitivity is limited typically to nM protein 
concentrations which leaves much of the proteome in plasma undetected.  Techniques 
like Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA) and 
Multiple Reaction Monitoring (MRM) can be more sensitive, but are still limited to tens 
of protein measurements2.  In addition, problems of cost, throughput, and 
reproducibility remain a challenge.  Due to these limitations, MS biomarker studies 
cannot yet be efficiently scaled to measure with sufficient sensitivity thousands of 
proteins in thousands of samples, and such studies therefore miss the greatest 
opportunity for discovery. 
In contrast to 2-D gels and MS, antibody-based methods are much more 
sensitive and can be used to detect analytes in the sub-nM range.  This is enabled by the 
high affinity of antibodies for their targets which is generally in the nM to pM range.  
However, non-specific binding of antibodies to non-cognate proteins, other 
macromolecules, and surfaces requires the use of sandwich-type assays where the 
second antibody contributes to enhanced specificity through an independent binding 
event.  In other words, technologies such as Enzyme-Linked Immuno-Sorbent Assays 
(ELISAs) attain high sensitivity by combining the specificity of two different antibodies 
to the same protein, requiring that both bind to elicit a signal1.  Although broadly used 
in single-analyte tests, it has recently become clear that such assays cannot be 
multiplexed above a few tens of simultaneous measurements3,4 in large part because 
cross-reactivity of secondary antibodies to surface-immobilized proteins (including 
primary antibodies) dramatically erodes specificity1.  This inherent characteristic 
compromises the performance of antibody-based arrays including printed antibodies, 
sandwich formats, and bead-based arrays1,5.  A recently reported proximity ligation 
assay that relies on antibody sandwich formation in solution followed by ligation of 
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antibody-tethered nucleic acids and PCR amplification has been multiplexed with six 
analytes3. 
Given these challenges, we set out to develop a proteomics array technology 
analogous to the highly-successful nucleic acid hybridization microarray.  To create this 
technology, we developed a new class of DNA-based aptamers enabled by a versatile 
chemistry technology that endows nucleotides with protein-like functional groups.  
These modifications greatly expand the repertoire of targets accessible to aptamers.  The 
resulting technology provides efficient, large-scale selection of exquisite protein binding 
reagents selected specifically for use in highly-multiplexed proteomics arrays.  Here we 
present the development of these unique reagents in the context of our high-content, 
high-performance, low-cost proteomics array, and demonstrate the potential of the 
platform to identify biomarkers from clinically-relevant samples. 
Aptamers are a class of nucleic acid-based molecules discovered twenty years 
ago6,7 and have since been employed in diverse applications including therapeutics8, 
catalysis9, and now proteomics.  Aptamers are short single-stranded oligonucleotides, 
which fold into diverse and intricate molecular structures that bind with high affinity 
and specificity to proteins, peptides, and small molecules10-12.  Aptamers are selected in 
vitro from enormously large libraries of randomized sequences by the process of 
Systematic Evolution of Ligands by EXponential enrichment (SELEX)6,7.  A SELEX 
library with 40 random sequence positions has 440 (~1024) possible combinations and a 
typical selection screens 1014-1015 unique molecules.  This is on the order of 105 times 
larger than standard peptide or protein combinatorial molecular libraries13.  
Based on the collective knowledge of the aptamer field that has developed since 
its inception6,7, we hypothesized that aptamers could make exceptional reagents for 
high-content proteomics.  There were many examples of high affinity RNA and DNA 
aptamers selected against human proteins12.  However, there were also examples of 
difficult protein targets for which standard RNA and DNA SELEX did not yield high 
affinity aptamers.  With two key innovations, we created a new class of aptamer, the 
Slow Off-rate Modified Aptamer (SOMAmer), which enabled efficient selection of 
high-affinity aptamers for almost any protein target. 
The first innovation was motivated by the idea that aptamers can be endowed 
with protein-like properties by adding functional groups that mimic amino acid side-
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chains to expand their chemical diversity14.  Eaton and colleagues developed the 
technology to efficiently synthesize nucleotides modified with diverse functional groups 
and to utilize them in SELEX14,15.  This innovation was used to select catalysts, 
including the first RNA-catalyzed carbon-carbon bond formation9,16.  Building on this 
work, we developed modified deoxyribonucleotides and SELEX methods17 to select 
modified DNA aptamers from libraries that incorporate one of four dUTPs modified at 
the 5-position (Fig. 1a and Supplementary Information (SI)).   
To test whether modified nucleotides improve SELEX, we compared selections 
with modified and unmodified nucleotides targeting thirteen “difficult” human proteins 
that repeatedly failed SELEX with unmodified DNA.  As a control, we included 
GA733-1 protein, which had yielded high-affinity aptamers with unmodified DNA 
SELEX.  The results (Supplementary Table 1) show that only SELEX with modified 
nucleotides yielded high-affinity aptamers to these difficult proteins.  It is worth noting 
that, depending on the protein, certain modifications worked better than others 
(Supplementary Table 1), illustrating the benefit of applying multiple modifications 
against the same target to ensure a high probability of success.  Based on these results, 
we adopted modified nucleotide SELEX exclusively in our standard selections.  To 
date, we have selected high-affinity aptamers (with most Kd values lower than nM, see 
Fig. 1b) to over 1000 human proteins, nearly all the proteins we have targeted. There are 
no obvious commonalities among those proteins that were initially unsuccessful in 
SELEX with unmodified DNA.  Overall, these results provide the first comprehensive 
evidence that modified nucleotides can expand the range of possible aptamer targets and 
improve their binding properties. 
The second innovation was a solution to the principal challenge of identifying a 
second element of specificity beyond binding of a second ligand for use in high-content 
arrays.  Inspired by classic kinetic theory of specific binding in complex mixtures18,19, 
we employed kinetic manipulations to help overcome the problem of non-specific 
SOMAmer-protein binding.  To achieve this second element of specificity, we selected 
for aptamers with slow dissociation rates (t1/2 >30 min, Fig. 1c) that allow selective 
disruption of non-specific (or non-cognate) binding interactions by using a large excess 
of a polyanionic competitor.  This kinetic challenge works well for two reasons.  First, 
dissociation rates of non-cognate SOMAmer-protein interactions are generally much 
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faster (half-lives of a few minutes or less).  Second, since all aptamers are polyanions, 
another polyanion at high concentration (e.g., dextran sulfate) can serve as a common 
competitor that dramatically minimizes rebinding events in a multiplex assay.  In 
contrast, a common non-denaturing competitor of all antibody-antigen interactions or, 
more generally, protein-protein interactions, is not known.  
The current array measures 813 human proteins (Supplementary Table 2).  
These proteins represent a wide range of sizes, physicochemical properties (e.g., pI 
range of 4-11 as shown in Fig. 1d), and biological functions from a variety of molecular 
pathways and gene families (Fig. 1e).  Thus, SOMAmer technology enables an efficient 
and scalable pipeline to generate unbiased content for proteomics arrays.   
To create our high-content proteomics discovery array, we developed a novel 
assay (Fig. 2) which transforms a complex proteomic sample (e.g., plasma, serum, 
conditioned media, cell lysates, etc.) into a quantified protein signature.  The assay 
leverages equilibrium binding and kinetic challenge1.  Both are carried out in solution, 
not on a surface, to take advantage of more favorable kinetics of binding and 
dissociation1.  Briefly, the sample is incubated with a mixture of SOMAmers each 
containing a biotin, a photocleavable group, and a fluorescent tag followed by capture 
of all SOMAmer-protein complexes on streptavidin beads (catch-1) (Fig. 2a, 2b-1,2).  
After stringent washing of the beads to remove unbound proteins and labeling of bead-
associated proteins with biotin under controlled conditions (Fig. 2b-3), the complexes 
are released from the beads back into solution by UV light irradiation and diluted into a 
high concentration of dextran sulfate, an anionic competitor.  Note that the biotin that 
was originally part of the SOMAmer now remains on beads.  The anionic competitor 
coupled with dilution selectively disrupts non-cognate complexes (see Fig. 3a) and since 
only the proteins now contain biotin, the complexes are re-captured on a second set of 
beads (catch-2) from which unbound SOMAmers are removed by a second stringent 
washing (Fig. 2b-5).  The SOMAmers that remain attached to beads are eluted under 
high pH-denaturing conditions and hybridized to sequence-specific complementary 
probes printed on a standard DNA microarray (Fig. 2b-6,7). 
The result is a mixture of SOMAmers that quantitatively reflects protein 
concentrations in the original sample.  The modified nucleotides in SOMAmers are 
designed to maintain canonical base-pairing17,20 (in a DNA duplex, adducts at the 5-
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position of pyrimidines are directed toward the major groove of DNA) and hybridize 
effectively to unmodified DNA oligonucleotides on the array (this, of course, is also 
required for replication during SELEX).  Thus, our assay takes advantage of the dual 
nature of aptamers as molecules capable of both folding into complex three-dimensional 
structures, which is the basis of their unique binding properties, and hybridization to 
specific capture probes. 
The assay uses one SOMAmer per analyte rather than a sandwich of binding 
reagents and thus depends on equilibrium binding and kinetics for specificity.  A key 
contribution to specificity in the assay is the difference in dissociation rates between 
cognate and non-cognate interactions as illustrated in Fig. 3a.  For example, the half-life 
of dissociation of kallistatin, LBP, and TIG2 SOMAmers from their cognate targets 
(determined by using unlabeled SOMAmers) are 65, 44, and 65 minutes, compared to 
<1 minute for dissociation of the same SOMAmers from histone H1.2, a known DNA 
binding protein.  Specific interactions are disrupted to a far lesser degree by dextran 
sulfate for all three SOMAmers (Fig. 3a).  This translates to substantial enrichment in 
the specific signal following kinetic challenge and the two-bead capture steps.   
It is worth noting that the use of sequential capture of protein-SOMAmer 
complexes on two sets of streptavidin beads, first through biotin-labeled SOMAmers 
(catch-1) and then through biotin-labeled proteins (catch-2), substantially reduces non-
specific interactions.  As shown in Fig. 3b, eluate from catch-1 beads generally contains 
the target protein as well as several other proteins that bind SOMAmers non-
specifically. Eluate from catch-2 beads contains only the target protein in substantially 
pure form, along with its cognate SOMAmer (for these experiments, reversible protein 
attachment to monomeric avidin catch-2 beads is used) (SI).  This is likely due, in part, 
to a reduction in the amount of total protein following catch-1 bead washing (only 
SOMAmer-bound or surface-bound proteins remain) as well as to release and recapture 
of complexes on separate beads in a reversed orientation (attachment through biotin on 
proteins). 
Finally, capture of SOMAmers on a hybridization array permits quantitative 
determination of the protein present in the original sample by converting the assay 
signal (relative fluorescence units, RFUs) to analyte concentration (Fig. 3c).  These 
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results show that specific SOMAmer-protein interactions can be detected efficiently in 
highly complex mixtures like serum or plasma. 
With this format, we achieved our goal of developing a high-content, high-
performance proteomics technology to power biomarker discovery in human disease.  
To assess the quantitative performance of the technology, we determined reproducibility 
and limits of quantification (LOQ).  The assay analyzes 96 samples per run.  We 
collected serum samples from 18 healthy volunteers and assayed five replicates of each 
sample in a single run and repeated this three times.  The results show an overall low 
median CV of ~5% for intra-run and inter-run CV.  We also determined the LOQ values 
of a representative subset (356) of target proteins in the context of all 813 SOMAmers 
(SI).  The median lower limit of quantification (LLOQ) was ~1 pM, with LLOQs as low 
as 100 fM for some proteins, a median upper limit of quantification (ULOQ) of ~1.5 
nM, and a median range of quantification (ROQ) of >3 logs.  We found consistent 
performance in serum for proteins with low endogenous concentrations when titrated 
into 10% serum and plasma (SI).  Overall, we achieve an ROQ for all proteins in a 
sample of ~7 logs (~100 fM – 1 M) with three sample dilutions that span ~2.5 logs.  
The content of the discovery array is flexible and highly scalable, permitting us to 
continue adding content as our SOMAmer menu increases.  This highly multiplexed 
technology therefore has the requisite reproducibility, sensitivity and range for high-
content proteomics studies and unbiased biomarker discovery. 
To demonstrate the utility of the platform in discovery of disease-related 
biomarkers, we analyzed plasma from subjects with chronic kidney disease (CKD), the 
slow loss of kidney function over time.  CKD is a recently recognized global public 
health problem that is “common, harmful, and treatable” with an estimated prevalence 
of nearly 10% worldwide21.  Early intervention in CKD can substantially improve 
prognosis, which is otherwise poor21-24.  To achieve early diagnosis, predictive, and 
non-invasive CKD biomarkers are needed. Such markers also would be useful for 
monitoring disease progression and guiding treatment21-24. 
 We chose CKD as a test case because kidney physiology provides filtration of 
serum molecules based on size (molecular mass) and charge25 – thus CKD might lead to 
an increase in the concentration of small proteins (MW <45 kDa).  Disease progression 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
10
.4
53
8.
1 
: P
os
te
d 
14
 J
un
 2
01
0
9 
is expected to be accompanied by an overall increase in plasma concentration of small 
proteins. 
We obtained and analyzed plasma samples from 42 subjects with CKD.  Eleven 
subjects had early-stage CKD based on estimated GFR (eGFR, defined as stages 1-2, 
median creatinine clearance 70 ml/min/m2, range 62-97 ml/min/m2) and 31 had late-
stage CKD (stages 3-5, median creatinine clearance 25 ml/min/m2, range 7-49 
ml/min/m2)26.  We measured 614 human proteins (array size at the time analyses were 
conducted) simultaneously for each sample and compared the results of early- to late-
stage CKD (Fig. 4a). 
We identified 60 proteins that varied significantly between the two groups, using 
the Mann-Whitney test, with a q-value (false discovery rate-corrected p-value) of 4.2 x 
10-4 (Supplementary Table 10).  Eleven proteins with the most highly significant 
variation (q-values <3.5 x 10-7) are highlighted in Fig. 4a and shown in Table 1.  Nine 
out of eleven are relatively small proteins (<25 kDa).  For all eleven proteins, there is an 
inverse correlation between eGFR and protein concentration (Fig. 4b), which supports 
the notion that these proteins are biomarkers for CKD progression.  It is also worth 
noting that two of the eleven proteins, cystatin C and β2-microglobulin, are important 
known biomarkers of CKD22-24 and two additional proteins, complement factor D and 
TNF sR-I, have been reported to have elevated concentrations in CKD27,2828,29. 
Accumulation in plasma of some small proteins appears to be a major change in 
the proteome.  However, the concentration of many low molecular weight proteins did 
not change appreciably with disease progression (Fig. 4c); pI also was uncorrelated with 
an increase in plasma concentration as a function eGFR (data not shown).  The 
surprising fact that the biomarkers are not simply ranked according to their molecular 
masses shows that reduced kidney function is complex.  The accumulation of some (but 
not all) low molecular weight proteins, sometimes called “middle molecules”, in plasma 
of patients with impaired renal filtration has long been implicated in the pathology of 
kidney disease29.  High-content proteomic analysis provides a means of unbiased 
discovery of such proteins and their relationship to disease progression.. 
This example demonstrates our ability to discover biomarkers to build diagnostic 
signatures of disease states for which there is an important medical need21-24.  
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Combining multiple biomarkers might create a high resolution picture of CKD to help 
develop diagnostic tools. 
In conclusion, we have presented the first highly multiplexed and efficient 
aptamer-based proteomics array technology that simultaneously measures large 
numbers of proteins ranging from low to high abundance in serum.  In CKD, we have 
identified a multitude of biomarkers with large differences in concentration between 
early- and late-stage disease.  Therefore, these biomarkers represent good candidates for 
use (alone or in combination) in diagnostic tests for CKD progression.  A study of more 
than 500 additional patients at risk for cardiovascular disease (whose eGFRs were also 
determined) confirmed and extended the biomarkers associated with reduced filtration 
in this first CKD study (data not shown). 
We have also conducted clinical studies in which no biomarkers have emerged.  
For example, in our prospective multicenter breast cancer study, we compared plasma 
proteomic signatures measuring 813 proteins (current array) of 336 women with 
suspicious mammogram findings.  Based on breast biopsy results, 32 women had ductal 
carcinoma in situ, 57 had invasive breast cancer and 247 had benign disease.  There 
were no statistically significant differences in the proteomic profile among these three 
groups.  These results, while disappointing, demonstrate that biomarkers are not 
identified by chance merely because thousands of measurements are made.  Of course, 
it is possible that with a larger array, new biomarkers of breast cancer will emerge. 
Our experience to date suggests that in most cases, biomarker discovery using 
our technology lies someplace between these extremes, with potentially useful 
biomarkers identified in many critical medical areas including cancer, cardiovascular 
conditions, neurological disorders, and infectious diseases.  Frequently, the distribution 
of biomarker concentrations among two populations contains considerable overlap 
which creates the impetus for combining multiple biomarkers to achieve the most 
accurate diagnosis.  In an accompanying paper30, we report the first large-scale 
application of our technology to discover and verify a novel biomarker panel for a major 
important medical condition, lung cancer, in one of the largest and most comprehensive 
proteomic biomarker studies to date. 
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METHODS SUMMARY 
We used rationally-designed, chemically-modified nucleotides to create a new class of 
aptamer – Slow Offrate Modified Aptamers (SOMAmers) – to use as protein binding 
reagents. We developed new SELEX methods, selected high affinity SOMAmers for 
>800 human proteins, and developed a highly multiplexed protein affinity assay that 
uses standard DNA quantification technologies as the final readout. We used affinity 
capture to demonstrate the specificity of SOMAmers for their target proteins. Assay 
reproducibility was measured with multiple technical replicates of serum and plasma. 
We determined the limits and range of quantification of target proteins with six-point, 
multiplexed standard curves of purified proteins in buffer. To demonstrate the utility of 
our new proteomics platform to discover potential biomarkers, we profiled 614 proteins 
in plasma samples from subjects with early-stage and late-stage CKD. The final readout 
was a custom DNA microarray.  We compared the resulting measurements with the 
non-parametric Mann-Whitney U Test because the data were non-normally distributed 
ordinal variables. For significance, we used an alpha cutoff of 4.3 x 10-04 for the q-value 
(p-value corrected for multiple comparisons using a false discovery rate estimate).  
Sixty of the 614 measured proteins were significantly different between early- and late-
stage CKD subjects. 
Full Methods and any associated references are available in the Supplementary 
Information. 
Supplementary Information is linked to the online version of the paper at www.nature.com/nature. 
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Tables 
Table 1. Top 11 Potential CKD Biomarkers a 
 
Target p-value q-value 
Mol. Mass 
(kDa) 
β2-Microglobulin 1.2 x 10-9 8.0 x 10-8 11.7 
FSTL3 1.2 x 10-9 8.0 x 10-8 25.0 
Pleotrophin 1.2 x 10-9 8.0 x 10-8 15.3 
TNF sR-I b, c 1.2 x 10-9 8.0 x 10-8 21.2 
Factor D 4.8 x 10-9 2.1 x 10-7 24.4 
IL-15 Rα b, d 4.8 x 10-9 2.1 x 10-7 25.0 
MMP-7 8.4 x 10-9 3.2 x 10-7 19.1 
Angiopoietin-2 1.4 x 10-8 3.5 x 10-7 54.9 
Cystatin C 1.4 x 10-8 3.5 x 10-7 13.3 
HCC-1b 1.4 x 10-8 3.5 x 10-7 8.7 
URB b  1.4 x 10-8 3.5 x 10-7 105.7 
 
a Based on q-value ranking 
b Smaller isoforms also exist.  For example, URB has a 10.3 kDa isoform 
c Extracellular domain comprising amino acids 22-211 
d Extracellular domain is 18.4 kDa 
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FIGURES 
Figure 1a 
 
 
Figure 1b 
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Figure 1d 
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Figure 2 
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 Figure 3b   
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Figure 4a 
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Figure 4c 
 
FIGURE LEGENDS 
Figure 1.  Unique properties of SOMAmers.  a, Nucleotide triphosphate analogs 
modified at the 5-position (R) of uridine (dUTP).  The 5-position modifications include: 
(A) 5-benzylaminocarbonyl-dU (BndU); (B) 5-naphthylmethylaminocarbonyl-dU 
(NapdU): (C) 5-tryptaminocarbonyl-dU (TrpdU); and (D) 5-isobutylaminocarbonyl-dU 
(iBudU).  b, Distribution of dissociation constant (Kd) values for 434 SOMAmers.  c, 
Distribution of dissociation rate constant (kd) values for 72 SOMAmers representative 
of those in proteomic arrays.  d, Distribution of isoelectric points (pI) of proteins for 
which SOMAmers have been selected (solid red bars) and of all human protein chains 
in UniProt (dashed blue line).  e, Distribution of most common gene ontology terms 
associated with the proteins measured by the current array. 
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Figure 2.  Principle of multiplex SOMAmer affinity assay.  a, Binding.  SOMAmers 
and samples are mixed in 96-well micro-well plates and allowed to bind.  Cognate and 
non-cognate SOMAmer-target protein complexes form.  Free SOMAmer and protein 
are also present.   b, Schematic sequence of assay steps leading to quantitative readout 
of target proteins.  (1) SOMAmer-protein binding: DNA-based SOMAmer molecules 
(gold, blue, and green) have unique shapes selected to bind to a specific protein.  
SOMAmers contain biotin (B), a photo-cleavable linker (L) and a fluorescent tag at the 
5’ end.  Most SOMAmers (gold and green) bind to cognate proteins (red), but some 
(blue) form non-cognate complexes.  (2) Catch-1.  SOMAmers are captured onto a bead 
coated with streptavidin (SA) which binds biotin.  Un-complexed proteins are washed 
away.  (3) Proteins are tagged with NHS-biotin.  (4) Photocleavage and kinetic 
challenge.  UV light (h) cleaves the linker and SOMAmers are released from beads, 
leaving biotin on bead.  Samples are challenged with anionic competitor (dextran 
sulfate).  Non-cognate complexes (blue SOMAmer) preferentially dissociate.  (5) Catch-
2 SOMAmer-protein complexes are captured onto new avidin coated beads by protein 
biotin tag. Free SOMAmers are washed away.  (6) SOMAmers are released from 
complexes into solution at high pH.  (7) Remaining SOMAmers are quantified by 
hybridization to microarray containing single-stranded DNA probes complementary to 
SOMAmer DNA sequence, which form a double-stranded helix.  Hybridized 
SOMAmers are detected by fluorescent tags when the array is scanned. 
 
Figure 3.  Kinetic discrimination between cognate and non-cognate interactions.  a,  
Dissociation rate measurements for specific and non-specific protein interactions with 
representative Kallistatin, LBP, and TIG2 SOMAmers.  Histone H1.2 binds to random 
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DNA sequences and was used to demonstrate non-specific binding.  The fraction of 
radiolabeled SOMAmer (10 pM) bound to its cognate target is shown after addition of 
50 nM unlabeled SOMAmer (■) or 0.3 mM dextran sulfate (▲) as a function of time.  
Rapid dissociation of non-specific complexes in the presence of 0.3 mM dextran sulfate 
is also shown.  b, SDS-PAGE visualization of representative proteins bound by the 
SOMAmers selected against Kallistatin, LBP and TIG2.  Gel 1 shows proteins bound to 
the Kallistatin SOMAmer for target added to buffer (lane 1), target added to 10% 
plasma (lane 2), and 10% plasma alone (lane 3).  The first set of three lanes 
demonstrates all of the proteins eluted from catch-1 beads.  The second set of lanes 
shows the SOMAmer-bound proteins eluted from catch-2 beads.  Gels 2 and 3 
demonstrate proteins recovered from 10% plasma using the LBP and TIG2 SOMAmers, 
respectively (without adding proteins to plasma for these three gels).  The endogenous 
plasma proteins captured by the Kallistatin, LBP, and TIG2 SOMAmers were identified 
by LC-MS/MS as the intended target proteins (data not shown).  c, Proteomics assay 
data for kallistatin, LBP and TIG2.  Each plot shows the standard curve with error bars 
for eight replicates of target spiked into buffer (blue symbols).  Triplicate measurements 
from diluted normal serum (red symbols) are plotted onto the standard curve, and the 
calculated normal concentrations in 100% serum are shown. 
 
Figure 4.  Biomarker discovery in CKD.  a, Distribution of the false discovery rate (q-
value) for the Mann-Whitney test statistic comparing late-stage vs. early-stage CKD for 
each protein measured (indicated as a bar on the x-axis) ordered as they appear on the 
array.  Eleven analytes with the smallest q-values (<3.5 x 10-7) are shown in red bars.  b, 
Protein concentrations (expressed as RFU values) as a function of renal clearance for 
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the eleven best biomarkers of late-stage (red symbols) vs. early-stage CKD (blue 
symbols).  c, Comparison of a protein’s molecular mass and the probability that it is a 
CKD biomarker (q-value (p-value corrected for false discovery rate)). 
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Supplementary Information 
Aptamer-based multiplexed proteomic technology for biomarker discovery 
 
SUPPLEMENTARY RESULTS 
 
SELEX with modified nucleotides 
In order to select SOMAmers with the novel modified nucleotides described 
above, we developed new methods to incorporate modified nucleotides into the SELEX 
process.  This included the synthesis of random libraries with modified nucleotides and 
the enzymatic amplification of SELEX pools that contain modified nucleotides.  Several 
enzymes were screened for the ability to incorporate these modified nucleotides, as well 
as to amplify a modified template.  We used Thermococcus kodakaraensis (KOD) DNA 
polymerase for PCR with a slightly modified buffer, although at low efficiency.  
Additionally, conditions have been defined to amplify selected DNA using a two-step 
process to avoid potential amplification biases.  These methods are detailed in the 
Materials and Methods section below. 
To test whether modified nucleotides improve SELEX to human proteins, we 
compared selections with modified and unmodified nucleotides against thirteen difficult 
human proteins for which unmodified SELEX had failed.  As a control, we included a 
protein that previously yielded high-affinity SOMAmers with unmodified SELEX.  The 
results of this experiment are shown in Table 1.  Only SELEX with modified nucleotides 
yielded high-affinity SOMAmers to the difficult proteins. 
We have selected SOMAmers to > 1000 human proteins.  We first implemented 
5-benzylaminocarbonyl-dU (BndU) in our high-throughput SELEX pipeline, and our 
success rate for selections to human proteins rose from < 30% to > 50% to a diversity of 
human proteins.  This supported our hypothesis that we could develop one SELEX 
protocol that would work repeatedly for very different proteins.  Since then, we have 
incorporated four modified nucleotides, BndU,  5-naphthylmethylaminocarbonyl-dU 
(NapdU), 5-tryptaminocarbonyl-dU (TrpdU), 5-isobutylaminocarbonyl-dU (iBudU).  
Since the incorporation of these modified nucleotides into SELEX experiments, our 
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success overall success rate (pool Kd < ~30nM) is ~84% (1204/1428) for high quality 
SOMAmers to a wide range of human proteins.  The 813 human proteins measured by 
the current array are shown in Table 2 (at the end of this document). 
 
Table 1. SELEX library affinities (Kd, M) with unmodified and modified nucleotides  
Target Protein dT BndU iBudU TrpdU
4‐1BBa failed 6 x 10‐9 failed 4 x 10‐9
B7a failed 1 x 10‐8 failed 7 x 10‐9
B7‐2a failed failed failed 6 x 10‐9
CTLA‐4a failed failed failed 1 x 10‐9
sE‐Selectina failed failed failed 2 x 10‐9
Fractalkine/CX3CL‐1 failed failed failed 5 x 10‐11
GA733‐1 proteina 9 x 10‐9 3 x 10‐9 5 x 10‐9 5 x 10‐10
gp130, solublea failed 6 x 10‐9 2 x 10‐8 1 x 10‐9
HMG‐1 failed failed 2 x 10‐8 5 x 10‐9
IR failed 2 x 10‐9 1 x 10‐8 2 x 10‐10
Osteoprotegerina 4 x 10‐8 5 x 10‐9 9 x 10‐9 2 x 10‐10
PAI‐1 failed 4 x 10‐10 9 x 10‐10 2 x 10‐10
P‐Cadherina failed 4x 10‐9 5 x 10‐9 3 x 10‐9
sLeptin Ra failed 2 x 10‐9 failed 5 x 10‐10
aThe protein used was expressed as a fusion to the Fc of human IgG1.  No detectable binding of the 
active library to an alternate Fc fusion protein was observed.  
 
SOMAmer Specificity 
We assessed the specificity of select SOMAmers for the targets they were 
selected against in an affinity binding assay that mimics our multiplexed proteomics 
assay.  The experimental method is outlined in Figure 1 and detailed below in the 
Materials and Methods section.  This experiment mimics Catch 1 and Catch 2 in the 
proteomics assay and then uses a third step to capture the bound SOMAmer-protein 
complex with an oligo that is complementary to a portion of the SOMAmer and acts as an 
affinity tag.  This “Catch 3” step is analogous to the DNA microarray hybridization step 
in the proteomics assay.  The captured complexes are then disrupted and the proteins are 
eluted and analyzed by denaturing poly-acrylamide gel electrophoresis (PAGE), as 
shown in Figure 3b (main document).  Not all complexes are able to be captured in the 
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“Catch 3” step, and therefore analyzed by PAGE, since the 3’ end of the SOMAmer is 
sometimes involved in its structure or interaction with the target.  Additional pull-down 
examples for the subset of the CKD-related targets whose complexes can be captured on 
“Catch 3” beads are shown in Figure 2. 
To further assess the specificity of selected (>20) SOMAmers for their target 
proteins, we excised the resulting PAGE gel samples (entire lanes) from the plasma 
affinity binding experiment described above and analyzed them by mass spectrometry 
(MS).  In all cases, the results confirmed that the gel band contained the target protein.  
This was evidenced by the identification of peptides that map to the target protein using 
their specific fragmentation patterns.  Peptides that mapped to other proteins were also 
identified, although the number of spectra for these proteins was typically much lower 
than for the specific target.  Such contaminants are a relatively small fraction because the 
PAGE gels show sharp uniform bands with very little background, which suggests that 
the majority of the material is the target protein. 
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Figure 1. Affinity binding pulldown assay. SOMAmers are mixed with the target sample 
(purified protein or plasma) and incubated to bind to equilibrium.  In Catch 1 bound 
SOMAmer(S)-protein(P) complexes are captured onto streptavidin beads (SA) and the proteins 
are tagged with biotin (B) (NHS- biotin) and fluorescent label (F) (NHS Alexa 647).  Unbound 
proteins are washed away.  Bound complexes are released from the beads by cleaving the photo-
cleavable linker (PC) with ultraviolet light.  In Catch 2 SOMAmer-protein complexes are 
captured onto monomeric avidin beads (A), washed, and eluted from the beads with 2 mM biotin.  
At this stage, SOMAmer-protein complexes are subjected to a kinetic challenge analogous to that 
used in the proteomics assay.  Specific complexes survive the challenge and non-specific 
complexes dissociate.  In the final step, Catch 3, bound complexes are captured onto primer 
beads (PB) by DNA primer that is complementary to a portion of the SOMAmer and any 
remaining unbound protein resulting from the kinetic challenge is washed away.  Finally, the 
captured complexes are dissociated with 20 mM NaOH and the target protein is eluted for 
analysis by PAGE. 
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Figure 2. Affinity assay pulldowns for SOMAmers selected against six CKD-related proteins 
show specificity of SOMAmers for their target proteins.  For each example the gel shows the 
results for purified target protein spiked into buffer (lane 1), purified target protein spiked into 
10% plasma (lane 2), and 10% plasma (lane 3).  The first set of three lanes demonstrates all of the 
proteins eluted from catch-1 beads.  The second set of lanes shows the aptamer-bound proteins 
eluted from catch-2 beads.   
 
 
Assay Reproducibility 
To assess the reproducibility of our proteomic measurements, we measured 
multiple replicate samples of serum and plasma in a single assay run.  Each run spans an 
entire 96-well microtiter plate.  Multiple replicate runs are performed and CVs are 
calculated for each analyte as a measure of reproducibility. 
Three independent automated assay runs (A, B, and C) were initiated and 
completed on two different days.  Each run was comprised of samples from eighteen 
different individuals run in five replicates along with six no-protein buffer controls to 
assess assay background.  See Materials and Methods below for detailed methods. 
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Reproducibility Measuring Plasma. The CV for each SOMAmer was computed 
for each sample by averaging over the replicates and then averaging these CVs over all 
the samples.  Both intra- and inter-plate CVs were computed for each dilution mix and 
are displayed in Figure 3 and summarized in Table 3 below.  The median intra- and inter-
plate CVs are 3.8% and 4.3% for SOMAmers in the 10% mix, 4.4% and 5.5% for 
SOMAmers in the 1% mix, and 5.6% and 6.8% for SOMAmers in the 0.03% mix. 
                         
Figure 3. Distributions for intra-run and inter-run CVs for plasma.  The cdfs for the intra-run 
CVs are on the left and the inter-run CVs are on the right for the three dilutions mixes, 10% (red), 
1% (green), and 0.03% (blue).  
 
 
                           
Intra-Run
 10.00% 1.00% 0.03%
0.05 2.28 2.66 3.57
0.25 2.94 3.70 4.67
0.50 3.85 4.40 5.63
0.75 5.24 5.27 7.87
0.95 9.31 9.15 12.22
Pr[X≤x] = 
x
 
Inter-Run
 10.00% 1.00% 0.03%
0.05 2.63 3.34 3.99
0.25 3.41 4.40 5.59
0.50 4.34 5.48 6.84
0.75 6.02 6.38 9.76
0.95 10.72 10.96 13.33
Pr[X≤x] = 
x
 
 
Table 3. Summary statistics for intra- and inter-run CVs broken out by plasma dilution (10%, 
1%, and 0.03%). 
 
Reproducibility Measuring Serum. The CV for each SOMAmer was computed for 
each sample by averaging over the replicates and then averaging these CVs over all the 
samples.  Both intra- and inter-plate CVs were computed for each dilution mix and are 
displayed in Figure 4 and summarized in Table 4 below.  The median intra- and inter-
plate CVs are 4.3% and 5.0% for SOMAmers in the 10% mix, 4.2% and 4.9% for 
SOMAmers in the 1% mix, and 5.3% and 6.4% for SOMAmers in the 0.03% mix 
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Figure 4. The distributions for intra-run and inter-run CVs for serum.  The cdfs for the intra-run 
CVs are on the left and the inter-run CVs are on the right for the three dilutions mixes, 10% (red), 
1% (blue), and 0.03% (green).  The inter-run CVs are only slightly higher than the intra-run CVs. 
 
 
              
Intra-Run
 10.00% 1.00% 0.03%
0.05 2.55 3.07 3.60
0.25 3.34 3.60 4.43
0.50 4.26 4.17 5.30
0.75 5.57 5.50 7.10
0.95 9.43 11.42 12.82
Pr[X≤x] = 
x
             
Inter-Run
 10.00% 1.00% 0.03%
0.05 2.96 3.67 4.27
0.25 3.94 4.35 5.24
0.50 4.97 4.93 6.39
0.75 6.62 6.45 8.39
0.95 11.36 13.97 15.94
Pr[X≤x] = 
x
 
 
Table 4. Summary statistics for intra- and inter-run CVs for serum. 
 
Limits and Ranges of Quantification 
 
In order to determine the quantitative performance of our proteomics platform, we 
generated precision profiles for 356 analytes.  The overall results are presented in Table 5 
at the end of this document.  A precision profile, which shows the variation in %CV for 
calculated concentration as a function of analyte concentration, provides an analytic 
measurement of assay performance and establishes the limits of quantification (LOQ) – 
both the upper and lower limits of quantification (ULOQ and LLOQ) – which define the 
dynamic range for analyte measurements.  We have focused on optimizing and assessing 
LLOQs in the assay.  Therefore, in some cases ULOQ measurements did not plateau in 
the measured range and represent a minimum estimate of ULOQ and, therefore, a 
minimum estimate of the range of quantification (ROQ). 
Buffer Experiments. The LOQ experiments measured six-point standard curves 
spanning six logs in concentration, from 10 nM to 10 fM, for a series of analytes in a 
multiplexed fashion.  A set of proteins was combined at the highest concentration and 
serially diluted 1:10 to create a set of standards that spanned six logs in concentration.  
Each analyte concentration was measured eight times to determine the assay error at each 
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concentration.  Approximately 90 proteins were combined and mixed with their 
respective SOMAmer dilution mixes for equilibration.  After Catch 1 these were 
combined for Catch 2 and hybridization as per standard assay protocol (see 
Supplementary Methods section below for assay details).  Two such runs fit on each 
dilution plate, yielding a total of 356 analyte measurements for precision profiles. 
Data Analysis. The precision profile was constructed from a series of standard 
curves.  The assay variance as a function of concentration was computed from these data.  
Typically, the relative error (CV), the standard deviation () of the calculated 
concentration divided by the concentration, is determined for computing LOQs.  As 
analyte concentration approaches zero, the assay CV diverges.  Similarly, for large 
analyte concentrations near the assay plateau, small changes in assay signal can give rise 
to large changes in calculated concentration, leading again to a divergence in CVs.  In 
between these two divergences in CVs lies a concentration range for which the assay 
measurements have CVs of a desired limit or less. 
We set this limit at 20% CV and determined the upper and lower LOQs as those 
high and low concentrations equal to 20% CV.  Standard curves were computed by 
averaging the relative fluorescent units (RFUs) for eight replicate measurements at each 
concentration.  A standard four parameter Hill model (Eq. 1) in log transformed RFU was 
used to fit the dose-response curves, where x denotes an analyte concentration.  
  baselinebaselineplateau RFUKx
xRFURFURFU log)log(loglog  

 (1) 
A typical dose-response curve from the data set is displayed in Figure 5. 
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Figure 5.  a2-Antiplasmin.  Dose-response curve using a four-parameter fit.  The average RFU at 
each concentration is denoted by the blue markers and the eight individual measurements used to 
compute the average are denoted by the red markers plotted on the curve fit (solid blue line). 
 
Two distinct approaches were used to compute precision profiles from these data.  
The first approach modeled the standard deviation for calculated concentrations x, 
obtained by averaging the eight replicates at each concentration, with a quadratic function 
from which the precision profile was directly obtained.  Figure 6 illustrates this approach 
for the analyte displayed in Figure 5.  The second approach is to model the standard 
deviation of the assay response logRFU with a quadratic function and then use the dose-
response function to compute the variance in concentration from the response variance.  
This is not easily accomplished for the dose-response function used here but linearizing 
the function at a concentration x leads to the following simplification (Eq. 2 and 3). 
     





x
RFU
RFU
x log
log     (2) 
 2
1
)log(loglog 

Kx
KxRFURFU
x
RFU
baselineplateau 



    (3) 
Typically, the assay CV in response units (logRFU /logRFU) is fairly constant so using a 
quadratic function to model RFU as a function of concentration should suffice.  Figure 7 
illustrates this for the data in Figure 5.  
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Figure 6.  Standard deviation of calculated concentration.  The standard deviation x for 
computed concentration is denoted by a blue marker.  The quadratic fit is displayed as a solid 
blue line and the 95% confidence bands for the fit are displayed as dashed lines.  
 
 
Figure 7.  Standard deviation of assay response.  The standard deviations for logRFUlogRFU are 
denoted by the red markers.  The quadratic fit is displayed as a solid red line and the 95% 
confidence bands for the fit are displayed as dashed lines.   
 
We produced the full precision profile for each SOMAmer tested using both 
numerical approaches outlined above.  The results for the analyte shown in Figure S5 are 
presented below in Figure S8 for (a) modeling x directly (blue line) and (b) modeling 
logRFU from which x is computed (red line).  Both methods give essentially the same 
result in this case for LLOQ and ULOQ.  This particular analyte shows a remarkable 
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five-log quantification range at a 20% CV cutoff with an LLOQ of 0.4-0.6 pM and a 
ULOQ of 40-50 nM.  In general there is good agreement between the two different 
methods for computing precision profiles, and the assay response logRFU method was 
used to calculate the values shown in Table 5. 
 
 
Figure 8.  Precision profiles for assay response computed from two different methods.  The 
precision profile computed by modeling x is displayed in blue and the profile for modeling 
logRFU is displayed in red.  The methods are consistent.  
 
Plasma versus Buffer LOQs.  The LLOQs, ULOQs, and range of quantification 
were computed for twenty-eight analytes as spikes into both plasma and buffer.  The 
results are summarized in Table 6 at the end of this document and in Figures S9-S11.  
The LOQs determined from spiking analytes into plasma and buffer agree well.  Both the 
LLOQs and the ULOQs are consistent between the two fluids; see Figures S9 and S10 
below.  The ranges of quantification are also in good agreement, see Figure 11, and are 
centered at 3 logs of dynamic range.  In general, these results illustrate that the 
quantitative behavior of our multiplexed assay, as characterized by precision profiles, is 
not affected by fluid matrix effects, allowing us to use protein spikes into buffer to assess 
the quantitative behavior of our multiplexed assay. 
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Figure 9.  Scatter plot of LLOQs Determined in Plasma and Buffer for 28 analytes.  These data 
were computed by modeling logRFU as described above. 
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Figure 10.  Scatter plot of ULOQs Determined in Plasma and Buffer for 28 analytes.  These data 
were computed by modeling logRFU as described above. 
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Figure 11.  Scatter plot of Ranges of Quantification Determined in Plasma and Buffer for 28 
analytes.  These data were computed by modeling logRFU as described above. 
 
LLOQ. The LLOQs were computed from the precision profiles of the analytes 
measured in buffer.  Greater than 95% of the analytes examined produced precision 
profiles with quantification ranges below a 20% CV cutoff.  The distribution of 
determined LLOQs is shown in Figure 12 and summarized in Table 7.  The median 
LLOQ is 0.9 pM and the inter-quartile range is 0.3 pM – 3.9 pM.  Over half of the 
analytes examined have LLOQs that are < 1.0 pM.  Although some analytes appear 
quantitative below 10 fM, these need to be verified with lower measurements. 
 
Figure 12.  Distribution of the LLOQs for 356 analytes.  The cumulative distribution function for 
LLOQ is displayed in the plot. 
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LLOQ
 x
0.05 4.4E-14
0.25 2.9E-13
0.50 9.4E-13
0.75 3.9E-12
0.95 7.9E-11
Pr[X≤x] = 
 
Table 7.  Summary of the LLOQs for 356 analytes. 
 
ULOQ. The distribution of determined ULOQs computed from the buffer 
precision profiles is given in Figure S13 and summarized in Table 8.  The median ULOQ 
is 1.5 nM and the inter-quartile range is 0.7 nM – 4.5 nM.  Although some analytes in the 
present analysis appear to be quantitative above 10 nM, these results need to be verified 
by making measurements higher than those in this study.  For example, albumin’s dose-
response curve is still increasing at 10 nM and so an accurate determination of the ULOQ 
is not possible from this data. 
 
 
 
Figure S13.  Distribution of the ULOQs for 356 analytes.  The cumulative distribution function 
for ULOQ is displayed in the plot. 
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ULOQ
 x
0.05 2.4E-10
0.25 7.0E-10
0.50 1.5E-09
0.75 4.5E-09
0.95 3.0E-08
Pr[X≤x] = 
 
Table 8.  Summary of the ULOQs for 356 analytes.  A summary of the ULOQ data is presented 
in the table. 
 
 Range of Quantification. The total quantitative range of quantification (ROQ) 
can be defined as the difference between log ULOQ and log LLOQ.  Based on the 
average LLOQ and ULOQ, the expected median quantification range is ~ 3 logs.  Figure 
S14 shows the distribution of the quantification range which is summarized in Table 9.  
The median range is 3.2 logs, consistent with the LOQs discussed above, and the center 
50% have ranges from 2.8-3.7 logs.  For those analytes that exceed four logs of 
quantification additional measurements are required for verification. 
 
 
 
Figure S14.  Distribution of the log quantification range for 356 analytes.  The cumulative 
distribution function for the log of the quantification range is displayed in the plot. 
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log Range
 x
0.05 1.9
0.25 2.8
0.50 3.2
0.75 3.7
0.95 4.3
Pr[X≤x] = 
 
Table 9.  Summary of the log quantification range for 356 analytes.  A summary of the 
quantification range data is presented in the table. 
 
A summary of the calculated LLOQ, ULOQ quantitative range for each analyte is 
provided in Table 5 at the end of this document.  The analytes have been grouped by their 
dilution mixes and sorted with respect to LLOQ.  In addition to the quantification 
metrics, the four parameters used in the dose-response curves are provided as well.  An 
entry of 10-6 M for LLOQ or ULOQ indicates that a limit has not been established from 
the data.  There are sixteen analytes for which both LLOQ and ULOQ are not determined 
and so the range is denoted as zero or the standard curves were not properly fit and so 
have no parameters listed.  Both these cases occur at the end of the lists.   
 
Chronic Kidney Disease Biomarkers 
 
 Table 10 lists sixty potential CKD biomarkers identified in this study comparing 
early- to late-stage disease with the Mann-Whitney U-test with an alpha of 4.3E-04 for 
the q-value (false discovery rate corrected p-value). 
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Table 10. Potential CKD Biomarkers 
Target p-value q-value Mol. Mass 
(kDa) 
β2-Microglobulin 1.19E-09 7.98E-08 11.7 
FSTL3 1.19E-09 7.98E-08 25.0 
Pleiotrophin 1.19E-09 7.98E-08 15.3 
TNF sR-I 1.19E-09 7.98E-08 48.3 
Factor D 4.77E-09 2.13E-07 24.4 
IL-15 Rα 4.77E-09 2.13E-07 25.0 
MMP-7 8.35E-09 3.19E-07 19.1 
Angiopoietin-2 1.43E-08 3.48E-07 55.1 
Cystatin C 1.43E-08 3.48E-07 13.3 
HCC-1 1.43E-08 3.48E-07 8.7 
URB 1.43E-08 3.48E-07 105.7 
Lysozyme 3.58E-08 7.36E-07 14.7 
ROR1 3.58E-08 7.36E-07 101.2 
Chordin-Like 1 5.37E-08 1.03E-06 48.8 
Endostatin 7.99E-08 1.43E-06 20.1 
Ephrin-A5 1.66E-07 2.61E-06 23.9 
Matrilin-2 1.66E-07 2.61E-06 104.4 
IGFBP-6 4.42E-07 6.56E-06 22.6 
Granzyme B 5.98E-07 8.41E-06 25.5 
DAN 1.06E-06 1.42E-05 17.7 
β-NGF 1.39E-06 1.69E-05 13.5 
Nectin-like protein 2 1.39E-06 1.69E-05 48.6 
CXCL16, soluble 1.82E-06 2.11E-05 24.2 
IGFBP-2 2.35E-06 2.51E-05 31.3 
SLPI 2.35E-06 2.51E-05 11.7 
TGF-β R III 3.84E-06 3.95E-05 91.3 
CNTFR α 4.87E-06 4.66E-05 35.8 
Lymphotoxin α1/β2 4.87E-06 4.66E-05 69.4 
CD48 7.51E-06 6.64E-05 22.3 
Lymphotoxin β R 7.69E-06 6.64E-05 43.7 
Troponin I 7.69E-06 6.64E-05 23.9 
ESAM 1.19E-05 9.63E-05 38.1 
NovH 1.19E-05 9.63E-05 35.7 
HCC-4 1.47E-05 1.15E-04 11.2 
CD30 Ligand 1.80E-05 1.30E-04 26.0 
MIA 1.80E-05 1.30E-04 12.1 
BCMA 2.20E-05 1.44E-04 20.1 
Insulysin 2.20E-05 1.44E-04 117.9 
Thrombospondin-1 2.20E-05 1.44E-04 128.0 
Trypsin 2.20E-05 1.44E-04 24.1 
Cystatin M 2.69E-05 1.71E-04 13.6 
Bcl-2 3.26E-05 1.89E-04 26.3 
Kallikrein 6 3.26E-05 1.89E-04 24.5 
LSAMP 3.26E-05 1.89E-04 31.8 
NKG2D 3.26E-05 1.89E-04 25.3 
Desmoglein-1 3.94E-05 2.07E-04 107.7 
Dtk 3.94E-05 2.07E-04 92.8 
EphA1 3.94E-05 2.07E-04 106.0 
MIP-3β 3.94E-05 2.07E-04 8.8 
Myoglobin 3.94E-05 2.07E-04 17.0 
Biglycan 4.74E-05 2.31E-04 37.2 
CD30 4.74E-05 2.31E-04 61.9 
IL-17D 4.74E-05 2.31E-04 20.3 
MIP-5 4.74E-05 2.31E-04 10.2 
Fractalkine/CX3CL-1 5.69E-05 2.72E-04 39.6 
IL-18 BPa 6.81E-05 3.19E-04 17.6 
GA733-1 protein 8.11E-05 3.68E-04 33.1 
Galectin-3 8.11E-05 3.68E-04 26.1 
bFGF-R 9.64E-05 4.23E-04 89.4 
PECAM-1 9.64E-05 4.23E-04 79.6 
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SUPPLEMENTARY METHODS 
 
SOMAmer development and SELEX 
Selection methods have been developed for use with poly-His-tagged, 
biotinylated, and non-tagged proteins.  Many variations on these protocol have been used 
to select the >800 SOMAmers for the proteomic platform, such as alternating selection 
conditions to increase stringency for slow off-rate SOMAmers or performing the 
equilibrium steps in solution rather than with targets pre-immobilized.  The following 
protocol is representative and was used for the selection described in the main text of this 
paper (results shown in Table 1).  Selection methods are further detailed in our patents 
and published patent applications1,2. 
Preparation of Candidate Mixtures.  Candidate mixtures were prepared with 
dATP, dGTP, 5-methyl-dCTP (MedCTP) and either dTTP or one of three dUTP analogs: 
5-benzylaminocarbonyl-dU (BndU),  5-tryptaminocarbonyl-dU = TrpdU, and 5-
isobutylaminocarbonyl-dU (iBudU) (Figure 1 of paper).  Candidate mixtures were 
prepared by polymerase extension of a primer annealed to a biotinylated template.  For 
each candidate mixture composition, 4.8 nmol forward PCR primer and 4 nmol template 
were combined in 100 L 1X Thermococcus kodakaraensis (KOD) XL DNA Polymerase 
Buffer (EMD), heated to 95C for 8 minutes, and cooled on ice.  Each 100 L 
primer:template mixture was added to a 400 L extension reaction containing 1X KOD 
DNA Polymerase Buffer, 0.125 U/L KOD DNA Polymerase, and  0.5 mM each dATP, 
MedCTP, dGTP, and dTTP or dUTP analog, and incubated 70C, 30 minutes.  Double-
stranded product was captured via the template strand biotins by adding 1 mL 
streptavidin-coated magnetic beads (MagnaBind Streptavidin, Pierce, 5 mg/mL in 1M 
NaCl + 0.05% TWEEN-20) and incubating 25C for 10 minutes with mixing.  Beads 
were washed three times with 0.75 mL SB1T Buffer (40 mM HEPES, pH 7.5, 125 mM 
NaCl, 5 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 0.05% TWEEN-20).  The SOMAmer 
strand was eluted from the beads with 1.2 mL 20 mM NaOH, neutralized with 0.3 mL 80 
mM HCl, and buffered with 15 L 1 M HEPES, pH 7.5.  Candidate mixtures were 
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concentrated with a Centricon-30 to approximately 0.2 mL, and quantified by UV 
absorbance spectroscopy.  
Immobilization of Target Proteins.  Target proteins were purchased with (His)6 
tags (R&D Systems, Millipore) and immobilized on Co+2-NTA paramagnetic beads 
(TALON, Dynal).  Target proteins were diluted to 0.2 mg/mL in 0.5 mL B/W Buffer (50 
mM Na-phosphate, pH 8.0, 300 mM NaCl, 0.01% TWEEN-20), and added to 0.5 mL 
TALON beads (pre-washed three times with B/W Buffer and resuspended to 10 mg/mL 
in B/W Buffer).  The mixture was rotated for 30 minutes at 25C and stored at 4C until 
use.  TALON beads coated with (His)6 peptide were also prepared and stored as above.  
Prior to use, beads were washed 3 times with B/W Buffer, once with SB1T, and 
resuspended in SB1T. 
SOMAmer Selection.  Affinity selections were performed separately with each 
candidate mixture, comparing binding between target protein beads (signal) and (His)6 
beads (background).  For each sample, a 0.5 µM candidate DNA mixture was prepared in 
40 µL SB1T.  1 L of 1 mM competitor oligo was added to the DNA, along with 10 L 
of a protein competitor mixture (0.1% HSA, 10 M casein, and 10 M prothrombin in 
SB1T).   
Binding reactions were performed by adding 50 L target protein-coated beads or 
(His)6-coated beads (5 mg/mL in SB1T) to the DNA mixture and incubating 37C for 15 
minutes with mixing.  The DNA solution was removed and the beads were washed 5 
times at 37C with SB1T containing 0.1 mg/mL herring sperm DNA (Sigma).  Unless 
indicated, all washes were performed by resuspending the beads in 100 L wash solution, 
mixing for 30 seconds, separating the beads with a magnet, and removing the wash 
solution.  Bound SOMAmers were eluted from the beads by adding 100 L SB1T + 2 M 
Guanidine-HCl and incubating 37C, 5 minutes with mixing.  The SOMAmer eluate was 
transferred to a new tube after magnetic separation.  After the first two selection rounds, 
the final two of five target beads washes were done for 5 minutes instead of 30 seconds. 
Primer beads were prepared by immobilizing biotinylated reverse PCR primer to 
streptavidin-coated paramagnetic beads (MyOne-SA, Dynal).  5 mL MyOne-SA beads 
(10 mg/mL) were washed once with NaClT (5 M NaCl, 0.01% TWEEN-20), and 
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resuspended in 5 mL biotinylated reverse PCR primer (5 M in NaClT).  The sample was 
incubated 25C, 15 minutes, washed twice with 5 mL NaClT, resuspended in 12.5 mL 
NaClT (4 mg/mL), and stored at 4C.    
25 L primer beads (4 mg/mL in NaClT) were added to the 100 L SOMAmer 
solution in Guanidine Buffer and incubated 50C, 15 minutes with mixing.  The 
SOMAmer solution was removed, and the beads were washed 5 times with SB1T.  
SOMAmer was eluted from the beads by adding 85 L 20 mM NaOH, and incubating 
37C, 1 minute with mixing.  80 L SOMAmer eluate was transferred to a new tube after 
magnetic separation, neutralized with 20 L 80 mM HCl, and buffered with 1 L 0.5M 
Tris-HCl, pH 7.5. 
SOMAmer Amplification and Purification.  Selected SOMAmer DNA was 
amplified and quantified by QPCR.  48 L DNA was added to 12 L QPCR Mix (5X 
KOD DNA Polymerase Buffer, 25 mM MgCl2, 10 M forward PCR primer, 10 µM 
biotinylated reverse PCR primer, 5X SYBR Green I, 0.125 U/L KOD DNA 
Polymerase, and 1 mM each dATP, dCTP, dGTP, and dTTP) and thermal cycled in an 
ABI5700 QPCR instrument with the following protocol:  1 cycle of 99.9C, 15 seconds, 
55C, 10 seconds, 70C, 30 minutes; 30 cycles of  99.9C, 15 seconds, 72C, 1 minute.  
Quantification was done with the instrument software and the number of copies of DNA 
selected with target beads and (His)6 beads were compared to determine 
signal/background ratios. 
Following amplification, the PCR product was captured on MyOne-SA beads via 
the biotinylated antisense strand.  1.25 mL MyOne-SA beads (10 mg/mL) were washed 
twice with 0.5 mL 20 mM NaOH, once with 0.5 mL SB1T, resuspended in 2.5 mL 3 M 
NaCl, and stored at 4C.  25 µL MyOne-SA beads (4 mg/mL in 3 M NaCl) were added to 
50 L double-stranded QPCR product and incubated 25C, 5 minutes with mixing.  The 
beads were washed once with SB1T, and the “sense” strand was eluted from the beads by 
adding 200 L 20 mM NaOH, and incubating 37C, 1 minute with mixing.  The eluted 
strand was discarded and the beads were washed 3 times with SB1T and once with 16 
mM NaCl.   
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SOMAmer sense strand was prepared with the appropriate nucleotide 
composition by primer extension from the immobilized antisense strand.  The beads were 
resuspended in 20 L primer extension reaction mix (1X KOD DNA Polymerase Buffer, 
1.5 mM MgCl2, 5 M forward PCR primer, 0.125 U/L KOD DNA Polymerase, 0.5 mM 
each dATP, MedCTP, dGTP, and either dTTP or dUTP analog) and incubated 68C, 30 
minutes with mixing.  The beads were washed 3 times with SB1T, and the SOMAmer 
strand was eluted from the beads by adding 85 L 20 mM NaOH, and incubating 37C, 1 
minute with mixing.  80 L SOMAmer eluate was transferred to a new tube after 
magnetic separation, neutralized with 20 L 80 mM HCl, and buffered with 5 L 0.1 M 
HEPES, pH 7.5. 
Selection Strategy and Feedback.  The relative target protein concentration of 
the selection step was lowered each round in response to the S/B ratio as follows: 
 
if S/B < 10, [P](i+1) = [P]i 
if 10 < S/B < 100, [P](i+1) = [P]i / 3.2 
if S/B > 100, [P](i+1) = [P]i / 10 
 
where [P] = protein concentration and i = current round number.  Target protein 
concentration was lowered by adjusting the mass of target protein beads (and (His)6 
beads) added to the selection step.  After each selection round, the convergence state of 
the enriched DNA mixture was determined.  5 L double-stranded QPCR product was 
diluted to 200 L with 4 mM MgCl2 containing 1X SYBR Green I.  Samples were 
overlaid with 75 L silicon oil and analyzed for convergence as follows. 
Nucleic Acid Reassociation Kinetics (C0t) Assay.  The sample was thermal 
cycled with the following protocol:  3 cycles of 98C, 1 minute, 85C, 1 minute; 1 cycle 
of 93C, 1 minute, 85C, 15 minutes.  During the 15 minutes at 85C, fluorescent images 
were measured at 5-second intervals.  The fluorescence intensity was plotted as a 
function of log (time) to evaluate the diversity of the sequences. 
Measurement of Equilibrium Binding Constants.  The equilibrium binding 
constants of the enriched libraries were measured using TALON bead partitioning.  
Radiolabled DNA was renatured by heating to 95C for 3 minutes in SB1T and slowly 
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cooling to 37C.  Complexes were formed by mixing a low concentration of DNA 
(~1x10-11 M) with a range of concentrations of target protein (1x10-7 M to 1x 10-12 M 
final) in SB1T, and incubating at 37C.  One-twelfth of each reaction was transferred to a 
nylon membrane and dried to determine total counts in each reaction.  25 g of MyOne 
TALON beads (Invitrogen) was added to the remainder of each reaction and mixed at 
37C for one minute.  Two-thirds of the reaction was then passed through a MultiScreen 
HV Plate (Millipore) under vacuum to separate protein-bound complexes from unbound 
DNA and washed with 100 L SB1T.  The nylon membrane and MultiScreen HV Plates 
were phosphorimaged and the amount of radioactivity in each sample quantified using a 
FUJI FLA-3000.  The fraction of captured DNA was plotted as a function of protein 
concentration and a non-linear curve-fitting algorithm was used to extract equilibrium 
binding constants (Kd values) from the data. 
Measurement of Dissociation Rate Constants.  The rate constant for 
SOMAmer:protein complex dissociation was determined for each aptamer by measuring 
the fraction of pre-formed aptamer:protein complexes that remain bound after addition of 
a competitor as a function of time.  Radiolabled SOMAmer was renatured as described 
above.  Approximately 5x10-11 M SOMAmer was equilibrated in SB18T (40 mM 
HEPES, 100 mM NaCl, 5 mM KCl, 5 mM MgCl2, 0.05% Tween-20 at pH 7.5) at 37C 
with protein at a concentration 10X greater than the measured Kd value.  Samples were 
then diluted 2X with 40 nM non-labeled SOMAmer or 0.3 mM dextran sulfate in SB18T 
at various time points.  Complexes were partitioned to separate free aptamer from 
protein:aptamer complexes.  The type of partitioning was dependent upon the protein 
used since not all proteins bind to the same type of partitioning resin.  For LBP and 
Histone H1.2, Zorbax PSM-300A (Agilent) resin was used for partitioning; for 
Kallistatin, MyOne TALON beads were used; for biotinylated-TIG2, MyOne 
Streptavidin beads were used.  Complexes were captured on the appropriate resin, and the 
sample was passed through a MultiScreen HV Plate under vacuum.  The samples were 
washed with SB18T.  The MultiScreen HV Plates were phosphorimaged and the amount 
of radioactivity in each sample quantified using a FUJI FLA-3000.  The fraction of 
complex remaining was plotted as a function of time, and the dissociation rate constant 
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was determined by fitting the data to an analytic expression for bimolecular dissociation 
kinetics using non-linear regression. 
Pull-down Assay.  50% plasma samples were prepared by EDTA-plasma 2X in 
SB18T with 2 M Z-Block_2 (the modified nucleotide sequence (AC-BnBn)7-AC).  The 
plasma spike samples were prepared by diluting 500 ng protein with the 50% plasma in 
SB17T (SB18T with 1 mM EDTA) with AEBSF and EGTA.  The plasma samples were 
prepared by diluting the 50% plasma in SB17T with AEBSF and EGTA.  The buffer 
spike samples were prepared by diluting 500 ng protein in SB17T with AEBSF and 
EGTA.  These samples were combined with 10 pmoles of SOMAmer to give final 
concentrations of 10% plasma, 2 mM AEBSF, 0.5 mM EGTA, and 100 nM SOMAmer.  
Complexes were formed by incubated at incubating at 37C for 45 minutes.  50 L of a 
20% slurry of Streptavidin agarose beads (ThermoFisher Scientific) was added to each 
sample and shaken for 10 minutes at room temperature.  The samples were added to a 
MultiScreen HV Plate to perform washes under vacuum filtration.  Each sample was 
washed one time quickly with 200 L of SB17T, one time for one minute with 200 L of 
100 M biotin in SB17T with shaking, one time with 200 L of SB17T for one minute 
with shaking, and one time with 200 L of SB17T for nine minutes with shaking.  
Proteins in the sample were labeled with both biotin and a fluorophore by incubating each 
samples in 100 L of 1 mM EZ Link NHS-PEO4-biotin (Pierce), 0.25 mM NHS-Alexa-
647 (Invitrogen) in SB17T for five minutes with shaking.  Each sample was washed one 
time with 200 L of 20 mM glycine in SB17T and five times with 200 L of SB17T, 
shaking each wash for one minute.  The final wash was removed using centrifugation at 
1000 rcf for 30 seconds.  The beads were resuspended with 100 L of SB17T.  
SOMAmers (complexed and free) were released from the beads by exposure under a 
BlackRay light source (UVP XX-Series Bench Lamps, 365 nm) for ten minutes with 
shaking.  The samples were spun out of the plate by centrifugation at 1000 rcf for 30 
seconds.  10 L of each sample was removed and reserved as “Catch 1 eluate” for SDS-
PAGE analysis.  The remainder of the samples was captured through the biotinylated 
proteins by adding 20 L of a 20% slurry of monomeric Avidin beads and shaking for ten 
minutes.  The beads were transferred to a MultiScreen HV Plate and washed four times 
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with 100 L of SB17T for one minute with shaking.  The final wash was removed using 
centrifugation at 1000 rcf for 30 seconds.  Proteins were eluted from the beads by 
incubating each sample with 100 L of 2 mM biotin in SB17T for five minutes with 
shaking.  Each eluate was transferred to 0.4 mg MyOne Streptavidin beads with a bound 
biotinylated-primer complementary to the 3’ fixed region of the SOMAmer.  The samples 
were incubated for five minutes with shaking to anneal the bead-bound fixed region to 
the SOMAmer complexes.  Each sample was washed two times with 100 L of 
1XSB17T for one minute each with shaking and one time with 100 L of 1XSB19T (5 
mM HEPES, 100 mM NaCl, 5 mM KCl, 5 mM MgCl2, 1mM EDTA, 0.05% Tween-20, 
pH 7.5) for one minute with shaking, all by magnetic separation.  The complexes were 
eluted by incubating with 45 L of 20 mM NaOH for two minutes with shaking.  40 L 
of each eluate was added to 10 L of 80 mM HCl with 0.05% Tween-20 in a new plate.  
10 L of each sample was removed and reserved as “Catch 2 aptamer-bound eluate” for 
SDS-PAGE analysis.  Gel samples were run on NuPAGE 4-12% Bis Tris Glycine gels 
(Invitrogen) under reducing and denaturing conditions according to the manufacturer’s 
directions.  Gels were imaged on an Alpha Innotech FluorChem Q scanner in the Cy5 
channel to image the proteins. 
 
SomaLogic Proteomic Affinity Assay Method 
 
 All steps were performed at room temperature unless otherwise indicated.  
Sample thawing and plating.  Aliquots of 100% serum or EDTA- plasma, stored at -
80°C, were thawed by incubating in a 25°C water bath for ten minutes.  After thawing the 
samples were stored on ice during mixing and prior to sample dilution.  Samples were mixed by 
gentle vortexing (setting # 4 on Vortex Genie) for 8 seconds.  A 20% sample solution was 
prepared by transferring 16 L of thawed sample into 96-well plates (Hybaid Omnitube 0.3 mL, 
ThermoFisher Scientific) containing 64 µL per well of the appropriate sample diluent at 4°C.  
Sample diluent for serum was 0.8x SB17 with 0.6 mM MgCl2, 2 mM EGTA, 2 M Z-Block_2, 
0.05% Tween and for EDTA-plasma was 0.8x SB18 with 0.8 mM MgCl2, 2 mM EGTA, 2 M 
Z-Block_2, 0.05% Tween.  This plate was stored on ice until the next sample dilution steps were 
initiated. 
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Preparation of 10%, 1% and 0.03% SOMAmer Solutions.  SOMAmers were grouped 
into three unique mixes.  The placing of a SOMAmer within a mix was empirically determined 
by assaying a dilution series of serum or plasma with each SOMAmer and identifying the sample 
dilution that gave the largest linear range of signal.  The segregation of SOMAmers and mixing 
with different dilutions of sample (10%, 1% or 0.03%) allow the assay to span a 107-fold range 
of protein concentration.  The composition of the custom SOMAmer mixes was slightly different 
between plasma and serum as expected due to variation in protein composition of these two 
media.  The custom stock SOMAmer solutions for 10%, 1% and 0.03% serum and plasma were 
prepared and stored at 8x concentration in SB17T.  
For each assay run, the three 8x SOMAmer solutions were diluted separately 1:4 into 
SB17T to achieve 2x concentration.  Each diluted SOMAmer master mix was heated to 95°C for 
five minutes and then to 37°C for 15 minutes.  55 µL of each 2x SOMAmer mix was manually 
pipetted into a 96-well plate resulting in three plates with 10%, 1% or 0.03% SOMAmer mixes.  
After mixing with sample, the final individual SOMAmer concentration ranged from 0.25-4 nM 
for serum, 0.5nM for plasma. 
Equilibration.  A 2% sample plate was prepared by diluting the 20% sample 1:10 into 
SB17T using the Beckman Coulter Biomek FxP.  A 0.06% sample plate was prepared by diluting 
the 2% sample plate 1:31 into SB17T.  The three sample dilutions were then transferred to their 
respective SOMAmer solutions by adding 55 µL of the sample to 55 µL of the appropriate 2x 
SOMAmer mix.  The plates were sealed with a foil seal (Plate Bio-Rad Microseal ‘F’ Foil, MJ 
Research) and incubated for 3.5 hours at 37°C. 
Preparation of Catch 1 Bead Plates.  133.3 µL of a 7.5% Streptavidin-agarose bead 
slurry in SB17T was added to each well of three pre-washed 0.45 um filter plates.  Each well of 
beads was washed once with 200 µL SB17T using vacuum filtration to remove the wash and 
then resuspended in 200 µL SB17T. 
Catch 1 Bead Capture.  All subsequent steps were performed by the Beckman Coulter 
Biomek FxP robot unless otherwise noted.  After the 3.5 hour equilibration, 100 µL of the 10%, 
1% and 0.03% equilibration binding reactions was transferred to their respective Catch 1 
Streptavidin agarose filter plates and incubated with shaking for ten minutes.  Unbound solution 
was removed via vacuum filtration.  Each set of Catch 1 beads was washed with 190 µL of 100 
µM biotin in SB17T and then 190 µL of SB17T using vacuum filtration to remove the wash.  
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190 µL SB17T was added to each well in the Catch 1 plates and incubated with shaking for ten 
minutes at 25°C.  The wash was removed via vacuum filtration and the bottom of the filter plates 
blotted to remove droplets using the on-deck blot station. 
Biotinylation of Proteins.  An aliquot of 100 mM NHS-PEO4-biotin  in DMSO was 
thawed at 37°C for six minutes and diluted to 1 mM with SB17T at pH 7.25.  100 µL of the 
NHS-PEO4-biotin was added to each well of each Catch 1 filter plate and incubated with 
shaking for five minutes.  Each biotinylation reaction was quenched by adding 150 µL of 20 mM 
glycine in SB17T to the Catch 1 plates with the NHS-PEO4-biotin.  Plates were incubated for 
one minute with shaking, vacuum filtrated, and 190 µL 20 mM glycine SB17T was added to 
each well in the plate.  The plates were incubated for one minute, shaking before removal by 
vacuum filtration.  190 µL of SB17T was added to each well and removed by vacuum filtration.  
The wells of the Catch 1 plates were subsequently washed three times by adding 190 µL SB17T, 
incubating for one minute with shaking followed by vacuum filtration.  After the last wash the 
plates were centrifuged at 1000 rpm for one minute over a 1 mL deep-well plate to remove 
extraneous volume before elution.  Centrifugation was performed off deck. 
Kinetic Challenge and Photo-Cleavage.  85 µL of 10 mM DxSO4 in SB17T was added 
to each well of the filter plates.  The filter plates were placed onto a Thermal Shaker (Eppendorf)  
under a BlackRay light source and irradiated for ten minutes with shaking.  The photo-cleaved 
solutions were sequentially eluted from each Catch 1 plate into a common deep well plate by 
centrifugation at 1000 rpm for one minute each.   
Catch 2 Bead Capture.  In bulk, MyOne-Streptavidin C1 beads were washed two times 
for 5 minutes each with equal volume of 20 mM NaOH and three times with an equal volume of 
SB17T.  Beads were resuspended in SB17T to a concentration of 10 mg/mL.  After resuspension, 
50 µL of this solution was manually pipetted into each well of a 96-well plate and stored at 4°C 
until Catch 2.  During Catch 2, the wash supernatant was removed via magnetic separation.  All 
of the photo-cleaved eluate was pipetted onto the MyOne magnetic beads and incubated with 
shaking for five minutes at 25°C.  The supernatant was removed from the MyOne beads via 
magnetic separation and 75 µL of SB17T was transferred to each well.  The plate was mixed for 
one minute at 37°C with shaking and then 75 µL of 60% glycerol (in SB17T) at 37°C was 
transferred to each well.  The plate was mixed for another minute at 37°C with shaking.  The 
wash was removed via magnetic separation.  These washes were repeated two more times.  After 
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removal of the third glycerol wash from the MyOne beads, 150 µL of SB17T was added to each 
well and the plates incubated at 37°C with shaking for one minute before removal by magnetic 
separation.  The MyOne beads were washed a final time using 150 µL SB19T with incubation 
for one minute, prior to magnetic separation. 
Catch 2 Bead Elution and Neutralization. SOMAmers were eluted from MyOne beads 
by incubating each well of beads with 105 µL of 100 mM CAPSO pH 10, 1 M NaCl, 0.05% 
Tween with shaking for five minutes.  90 µL of each eluate was transferred during magnetic 
separation to a new 96-well plate containing 10 µL of 500 mM HCl, 500 mM HEPES, 0.05% 
Tween-20. 
Hybridization.  20 µL of each neutralized catch 2 eluate was transferred to a new 96-
well plate and 5 µL of 10x Agilent Block (Oligo aCGH/ChIP-on-chip Hybridization Kit, Large 
Volume, Agilent 5188-5380), containing a 10x spike of hybridization controls (10 Cy3 
SOMAmers) was added to each well.  After removing the plate from the robot, 25 µL of 2x 
Agilent Hybridization buffer (Oligo aCGH/ChIP-on-chip Hybridization Kit) was manually 
pipetted to the each well of the plate containing the neutralized samples and blocking buffer.  40 
µL of this solution was manually pipetted into each “well” of the hybridization gasket slide 
(Hybridization Gasket Slide - 8 microarray per slide format, Agilent).  Custom Agilent 
microarray slides containing 10 probes per array complementary to 40 nucleotide selected region 
of each SOMAmer with a 20x dT linker were placed onto the gasket slides according to the 
manufacturer’s protocol.  Each assembly (Hybridization Chamber Kit - SureHyb enabled, 
Agilent) was tightly clamped and loaded into a hybridization oven for 19 hours at 60°C rotating 
at 20 rpm. 
Post Hybridization Washing.  Approximately 400 mL Wash Buffer 1 (Oligo 
aCGH/ChIP-on-chip Wash Buffer 1, Agilent) was placed into each of two separate glass staining 
dishes.  Six of the twelve slide/gasket assemblies were sequentially disassembled into the first 
staining dish containing Wash Buffer 1.  Once disassembled, the slide was quickly transferred 
into a slide rack in a second staining dish containing Wash Buffer 1.  The slides were incubated 
for five minutes in Wash Buffer 1 with mixing via magnetic stir bar.  The slide rack was then 
transferred to the 37°C Wash Buffer 2 (Oligo aCGH/ChIP-on-chip Wash Buffer 2, Agilent) and 
allowed to incubate for five minutes with stirring.  The slide rack was transferred to a fourth 
staining dish containing acetonitrile and incubated for five minutes with stirring. 
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Microarray Imaging.  The microarray slides were imaged with a microarray scanner 
(Agilent G2565CA Microarray Scanner System) in the Cy3-channel at 5 m resolution at 100% 
PMT setting and the XRD option enabled at 0.05.  The resulting tiff images were processed 
using Agilent feature extraction software version 10.5.1.1 with the GE1_105_Dec08 protocol. 
 
Serum and Plasma Reproducibility Studies  
 
For each plate, five aliquots of plasma or serum from 18 individuals were thawed and 
plated as described below.  Six wells containing only buffer were run on every plate.  Serum and 
plasma samples were run on separate plates because they require slightly different buffers as 
indicated above.  Three plates of each sample type were run over the course of several days and 
included using different lots of buffers and other reagents that might be expected to change 
within a large study.   
 
Limits of Quantification (LOQ) Experiment  
 
For the LOQ experiments, four different sets of protein mixes were prepared for each of 
the three SOMAmer mixes, 10%, 1% or 0.03%, for a total of 12 mixes and 356 proteins.  The 
proteins for each mix were chosen to avoid combining known protein binding partners and 
known protease-substrate pairs.  
The proteins were diluted into SB17T containing 2 µM Z-Block_2 so that each protein 
was at a final concentration of 20 nM.  The protein solutions were serially diluted 15.8-fold into 
SB17T for a total of six points (lowest concentration: 20.3 fM).  All of the protein preparation 
was maintained on ice.  Eight replicate protein titrations per set were pipetted into 96-well plates. 
 
Clinical Data Processing 
 
Assay Normalization.  Assay normalization was performed to reduce signal 
variation potentially introduced during the assay.  Each sample in a study was normalized 
using a set of SOMAmers that have the lowest overall relative signal variation across all 
samples within a study.  For each normalization SOMAmer, its median value was 
calculated from all samples in the study, and together these median values were used to 
calculate a scaling factor for each individual sample.  The scaling factor was the mean of 
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a series of values, one for each normalization SOMAmer, calculated as the sample signal 
divided by the median signal for the study.  When applied to a sample, this procedure 
brings the signals corresponding to SOMAmers in the normalization set closer to the 
median values across the assay, and reduces the observed variation between replicate 
samples for all SOMAmers.  Because the assay splits each clinical sample into three 
dilutions, assay normalization was performed separately on the three SOMAmer groups 
corresponding to the 10%, 1%, and 0.1% dilutions.  Dilution normalization applies the 
same constant factor to every signal in that dilution from any given sample.  This factor 
varied between samples in the range from 0.8 to 1.2, and was typically within 10% of 
unity. 
Between Run Calibration.  To compare samples between assay runs with 
slightly different conditions, we have applied calibration to the individual SOMAmers 
signals.  For this we apply a multiplicative correction factor specific to each SOMAmer, 
but invariant with respect to the sample (in contrast to normalization in which the factor 
was specific to the sample and did not vary from SOMAmer to SOMAmer within a 
sample).  To calculate the calibration constant for each SOMAmer, we measure a set of 
eight calibrator samples derived from blood from the same individual in each sample set.  
From these calibrator sample measurements, we can standardize the signals from a 
sample within one run by applying the calibration coefficient for each SOMAmer that 
scales the median calibrator signal of that aptamer to a reference standard for that 
aptamer. 
 
Chronic Kidney Disease 
 
 CKD serum samples were collected by the Rogosin Institute for the clinical study 
entitled “Quantification of inflammatory and immune mediators of CKD in patient 
serum, whole blood and urine: Correlation with CKD disease stage progression”.  Both 
the original study and the biomarker study reported here were approved by the 
Institutional Review Board at Weil Medical College of Cornell University.  The clinical 
study design specified that samples be collected from 25 healthy controls with no renal 
disease and 25 subjects at each stage of CKD (1-5) for a total of 150 subjects.  Our 
biomarker study included serum samples from 55 subjects that were available at the time 
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this study was conducted.  Table 11 summarizes the population demographics.  The 
groups are well matched by gender, ethnicity, age, weight and body mass index.  Renal 
function, measured by the estimated glomerular filtration rate (eGFR, calculated with the 
MDRD formula for creatinine clearance3), is substantially different in the two groups (see 
figure S15). 
 
Table 11. CKD Population Demographics 
 Early stage CKD Late stage CKD 
N (total = 42) 11 31 
Gender %F (F/M) 33% (4/11) 45% (14/31) 
Ethnicity (A/B/C/H)a 1/5/1/4 2/9/0/20 
Age (avg. yrs) 62 [51-68] 67 [57-77] 
Wt. (avg. kg) 89 [73-98] 88 [75-104] 
BMI (avg.) 30.5 [26.6-36.5] 31.8 [27.1-36.6] 
eGFR (median)b 70 [62-97] 25 [7-49] 
aA, Asian; B, African American; C, Caucasian; H, Hispanic 
bEstimated glomerular filtration from creatinine clearance (MDRD formula) ml/min/m2 
 
 
 
Figure S15. Renal function (eGFR) in diabetic patients stratified into 18 early stage 
subjects (CKD Stage 1-3) and 37 late stage subjects (CKD Stage 4-5). 
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Target Uni-Prot Protein Name Uni-Prot Acc # CKD
14-3-3 protein zeta/delta 14-3-3 protein zeta/delta P63104
4-1BB Tumor necrosis factor receptor superfamily member 9 Q07011 Y
4-1BB ligand Tumor necrosis factor ligand superfamily member 9 P41273
6Ckine Small-inducible cytokine A21 O00585 Y
α1-Antichymotrypsin Alpha-1-antichymotrypsin P01011 Y
α1-Antitrypsin Alpha-1-antitrypsin P01009
α2-Antiplasmin Alpha-2-antiplasmin P08697 Y
α2-HS-Glycoprotein Alpha-2-HS-glycoprotein P02765
α2-Macroglobulin Alpha-2-macroglobulin P01023
ABL1 Proto-oncogene tyrosine-protein kinase ABL1 P00519 Y
ABL2 Tyrosine-protein kinase ABL2 P42684 Y
ACE-2 Angiotensin-converting enzyme 2 Q9BYF1 Y
Activated Protein C Vitamin K-dependent protein C (activated form) P04070 Y
Activin A Inhibin beta A chain P08476 Y
Activin RIB Activin receptor type-1B P36896 Y
ADAM 9 Disintegrin and metalloproteinase domain-containing protein 9 Q13443
ADAMTS-1 ADAMTS-1 Q9UHI8
ADAMTS-4 ADAMTS-4 O75173 Y
ADAMTS-5 ADAMTS-5 Q9UNA0 Y
ADAMTS-13 ADAMTS-13 Q76LX8 Y
Adenosylhomocysteinase Adenosylhomocysteinase P23526
Adiponectin Adiponectin Q15848
aFGF Heparin-binding growth factor 1 P05230 Y
AGGF1 Angiogenic factor with G patch and FHA domains 1 Q8N302 Y
Aggrecan Aggrecan core protein P16112 Y
AgRP Agouti-related protein O00253 Y
AIF-1 Allograft inflammatory factor 1 P55008 Y
AIP AH receptor-interacting protein O00170
Albumin Serum albumin P02768
ALCAM Activated leukocyte cell adhesion molecule Q13740 Y
aldolase A Fructose-bisphosphate aldolase A P04075
ALK-1 Serine/threonine-protein kinase receptor R3 P37023 Y
Alkaline phosphatase, bone Alkaline phosphatase, tissue-nonspecific isozyme P05186 Y
ALT Alanine aminotransferase 1 P24298
Aminoacylase-1 Aminoacylase-1 Q03154 Y
amphiregulin Amphiregulin P15514 Y
amyloid precursor protein Amyloid beta A4 protein P05067
Angiogenin Angiogenin P03950 Y
Angiopoietin-1 Angiopoietin-1 Q15389 Y
Angiopoietin-2 Angiopoietin-2 O15123 Y
Angiopoietin-4 Angiopoietin-4 Q9Y264 Y
Angiostatin Angiostatin P00747
Angiotensinogen Angiotensinogen P01019 Y
Angplt4 Angiopoietin-related protein 4 Q9BY76
Angptl3 Angiopoietin-related protein 3 Q9Y5C1 Y
Antithrombin III Antithrombin-III P01008 Y
Apo A-I Apolipoprotein A-I P02647 Y
Apo B Apolipoprotein B-100 and Apolipoprotein B-48 P04114 Y
Apo E Apolipoprotein E P02649 Y
Apo E2 Apolipoprotein E (isoform E2) P02649 Y
Apo E3 Apolipoprotein E (isoform E3) P02649 Y
Apo E4 Apolipoprotein E (isoform E4) P02649 Y
ApoE R2 Low-density lipoprotein receptor-related protein 8 Q14114 Y
APRIL Tumor necrosis factor ligand superfamily member 13 O75888 Y
Arginase-1 Arginase-1 P05089 Y
ARID3A AT-rich interactive domain-containing protein 3A Q99856
ARSB Arylsulfatase B P15848 Y
Artemin Artemin Q5T4W7 Y
Arylsulfatase A Arylsulfatase A P15289
Table 2. Protein Target Menu
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ASAH2 Neutral ceramidase Q9NR71 Y
ASAHL N-acylethanolamine-hydrolyzing acid amidase Q02083
ASGPR1 Asialoglycoprotein receptor 1 P07306
Aurora B Serine/threonine-protein kinase 12 Q96GD4 Y
Aurora kinase A Serine/threonine-protein kinase 6 O14965 Y
Azurocidin Azurocidin P20160 Y
β2-Microglobulin Beta-2-microglobulin P61769 Y
B7 T-lymphocyte activation antigen CD80 P33681 Y
β-Endorphin Beta-endorphin P01189 Y
β-NGF Beta-nerve growth factor P01138 Y
BAFF Tumor necrosis factor ligand superfamily member 13B Q9Y275 Y
BAFF Receptor Tumor necrosis factor receptor superfamily member 13C Q96RJ3
BARK1 Beta-adrenergic receptor kinase 1 P25098 Y
BCA-1 Small-inducible cytokine B13 O43927
BCAM Lutheran blood group glycoprotein P50895 Y
Bcl-2 Apoptosis regulator Bcl-2 P10415 Y
BCL2A1 Bcl-2-related protein A1 Q16548 Y
BCMA Tumor necrosis factor receptor superfamily member 17 Q02223 Y
BDNF Brain-derived neurotrophic factor P23560 Y
bFGF Heparin-binding growth factor 2 P09038 Y
bFGF-R Basic fibroblast growth factor receptor 1 P11362 Y
βIGH3 Transforming growth factor-beta-induced protein ig-h3 Q15582 Y
Biglycan Biglycan P21810 Y
BMP RII Bone morphogenetic protein receptor type-2 Q13873 Y
BMP-1 Bone morphogenetic protein 1 P13497 Y
BMP10 Bone morphogenetic protein 10 O95393
BMP-14 Growth/differentiation factor 5 P43026 Y
BMP-6 Bone morphogenetic protein 6 P22004
BMP-7 Bone morphogenetic protein 7 P18075 Y
BMPER BMP-binding endothelial regulator protein Q8N8U9 Y
BMPR1A Bone morphogenetic protein receptor type IA P36894
BMX Cytoplasmic tyrosine-protein kinase BMX P51813 Y
BNP-32 Brain natriuretic peptide 32 P16860
Bone proteoglycan II Decorin P07585 Y
BPI Bactericidal permeability-increasing protein P17213 Y
Brevican Brevican core protein Q96GW7
BSP Bone sialoprotein 2 P21815 Y
BTK Tyrosine-protein kinase BTK Q06187 Y
C1q Complement C1q subcomponent subunits A, B, and C P02747,P02746,P02745 Y
C1r Complement C1r subcomponent P00736 Y
C1s Complement C1s subcomponent P09871
C2 Complement C2 P06681 Y
C3 Complement C3 P01024 Y
C3a C3a anaphylatoxin P01024 Y
C3adesArg C3a anaphylatoxin des Arginine P01024 Y
C3b Complement C3b P01024 Y
C3d Complement C3d fragment P01024 Y
C4 Complement C4-A and Complement C4-B P0C0L4, P0C0L5 Y
C4b C4b-A P0C0L4 P0C0L5 Y
C5 Complement C5 P01031 Y
C5a C5a anaphylatoxin P01031 Y
C5b,6 Complex Complement C5b, and Complement component C6 P01031 P13671 Y
C6 Complement component C6 P13671 Y
C7 Complement component C7 P10643 Y
C8 Complement component C8 alpha, beta, and gamma chains P07357,P07358,P07360 Y
C9 Complement component C9 P02748 Y
Cadherin-1 Epithelial cadherin P12830 Y
Cadherin-2 Neural cadherin P19022
Cadherin-5 Vascular endothelial cadherin P33151 Y
Cadherin-6 Kidney cadherin P55285
Cadherin-12 Brain cadherin P55289 Y
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Calcineurin B α Calcineurin subunit B type 1 P63098
Calpain I Calpain-1 catalytic subunit and Calpain small subunit 1 P07384, P04632 Y
Calpastatin Calpastatin P20810 Y
CAMK1 Calcium/calmodulin-dependent protein kinase type 1 Q14012
CAMK1D Calcium/calmodulin-dependent protein kinase type 1D Q8IU85 Y
CAMK2A Calcium/calmodulin-dependent protein kinase type II alpha chain Q9UQM7 Y
CAMK2B Calcium/calmodulin-dependent protein kinase type II beta chain Q13554 Y
CAMK2D Calcium/calmodulin-dependent protein kinase type II delta chain Q13557 Y
CaMKK α Calcium/calmodulin-dependent protein kinase kinase 1 Q8N5S9
Carbonic anhydrase III Carbonic anhydrase 3 P07451
Carbonic anhydrase IV Carbonic anhydrase 4 P22748 Y
Carbonic anhydrase VI Carbonic anhydrase 6 P23280 Y
Carbonic anhydrase VII Carbonic anhydrase 7 P43166 Y
Carbonic anhydrase IX Carbonic anhydrase 9 Q16790
Carbonic anhydrase XIII Carbonic anhydrase 13 Q8N1Q1 Y
Carbonic anhydrase-related protein X Carbonic anhydrase-related protein 10 Q9NS85 Y
Cardiotrophin-1 Cardiotrophin-1 Q16619 Y
Carnosine dipeptidase 1 Beta-Ala-His dipeptidase Q96KN2
Caspase-3 Caspase-3 (pro form) P42574
Catalase Catalase P04040 Y
Cathepsin A Lysosomal protective protein P10619 Y
Cathepsin B Cathepsin B P07858 Y
Cathepsin C Dipeptidyl-peptidase 1 P53634
Cathepsin D Cathepsin D P07339
Cathepsin E Cathepsin E P14091
Cathepsin G Cathepsin G P08311 Y
Cathepsin H Cathepsin H P09668
Cathepsin S Cathepsin S P25774 Y
Cathepsin V Cathepsin L2 O60911 Y
CCL1 Small-inducible cytokine A1 P22362 Y
CCL28 Small-inducible cytokine A28 Q9NRJ3 Y
CD22 B-cell receptor CD22 P20273 Y
CD23 Low affinity immunoglobulin epsilon Fc receptor P06734 Y
CD30 Tumor necrosis factor receptor superfamily member 8 P28908 Y
CD30 Ligand Tumor necrosis factor ligand superfamily member 8 P32971 Y
CD36 ANTIGEN Platelet glycoprotein 4 P16671 Y
CD39 Ectonucleoside triphosphate diphosphohydrolase 1 P49961 Y
CD40 ligand, soluble CD40 ligand P29965
CD48 CD48 antigen P09326 Y
CD5L CD5 antigen-like O43866 Y
CD70 CD70 antigen P32970
CD97 CD97 antigen P48960 Y
CD109 CD109 antigen Q6YHK3
CDC37 Hsp90 co-chaperone Cdc37 Q16543
CDK1/cyclin B Cell division control protein 2 homolog, G2/mitotic-specific cyclin-
B1 Complex
P06493, P14635 Y
CDK2/cyclin A Cell division protein kinase 2, Cyclin-A2 Complex P24941, P20248 Y
CDK5/p35 Cell division protein kinase 5, Cyclin-dependent kinase 5 activator 
1, p35 Complex
Q00535, Q15078 Y
CDK8/cyclin C Cell division protein kinase 8, Cyclin-C Complex P49336, P24863 Y
CEA Carcinoembryonic antigen-related cell adhesion molecule 5 P06731
Chemerin Retinoic acid receptor responder protein 2 Q99969 Y
Chitotriosidase-1 Chitotriosidase-1 Q13231
Chk1 Serine/threonine-protein kinase Chk1 O14757 Y
Chk2 Serine/threonine-protein kinase Chk2 O96017 Y
CHL1 Neural cell adhesion molecule L1-like protein O00533
Chordin-Like 1 Chordin-like protein 1 Q9BU40 Y
Chymase Chymase P23946 Y
CK-BB Creatine kinase B-type P12277 Y
CK-MB Creatine kinase B-type, Creatine kinase M-type P12277, P06732
CK-MM Creatine kinase M-type P06732 Y
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Ck-β-8-1 Small-inducible cytokine A23 P55773 Y
CLF-1/CLC Complex Cytokine receptor-like factor 1 and Cardiotrophin-like cytokine 
factor 1
O75462, Q9UBD9 Y
CN166 UPF0568 protein C14orf166 Q9Y224
CNTF Ciliary neurotrophic factor P26441 Y
CNTFR α Ciliary neurotrophic factor receptor alpha P26992 Y
Coagulation Factor V Coagulation factor V P12259 Y
Coagulation Factor VII Coagulation factor VII P08709 Y
Coagulation Factor IX Coagulation factor IX P00740 Y
Coagulation Factor IXab Coagulation factor IX  (activated form) P00740 Y
Coagulation Factor X Coagulation factor X P00742 Y
Coagulation Factor Xa Coagulation factor X (activated form) P00742 Y
Coagulation Factor XI Coagulation factor XI P03951 Y
COLEC12 Collectin-12 Q5KU26 Y
COMMD7 COMM domain-containing protein 7 Q86VX2 Y
complement factor H-related 5 Complement factor H-related protein 5 Q9BXR6
Contactin-1 Contactin-1 Q12860 Y
Contactin-2 Contactin-2 Q02246 Y
Contactin-4 Contactin-4 Q8IWV2 Y
Contactin-5 Contactin-5 O94779 Y
COX-2 Prostaglandin G/H synthase 2 P35354 Y
Cripto Teratocarcinoma-derived growth factor 1 P13385 Y
CRISP-3 Cysteine-rich secretory protein 3 P54108 Y
CRP C-reactive protein P02741
Cryptic Cryptic protein Q9GZR3 Y
CSK Tyrosine-protein kinase CSK P41240
CSK21 Casein kinase II subunit alpha P68400 Y
CTACK Small-inducible cytokine A27 Q9Y4X3 Y
CTGF Connective tissue growth factor P29279 Y
CTLA-4 Cytotoxic T-lymphocyte protein 4 P16410 Y
CXCL16, soluble Small-inducible cytokine B16 Q9H2A7 Y
Cyclophilin A Peptidyl-prolyl cis-trans isomerase A P62937
Cystatin C Cystatin-C P01034 Y
Cystatin D Cystatin-D P28325
Cystatin F Cystatin-F O76096 Y
Cystatin M Cystatin-M Q15828 Y
Cystatin S Cystatin-S P01036
Cystatin SN Cystatin-SN P01037 Y
Cytochrome c Cytochrome c P99999 Y
Cytochrome P450 3A4 Cytochrome P450 3A4 P08684 Y
DAN Neuroblastoma suppressor of tumorigenicity 1 P41271 Y
DAPK2 Death-associated protein kinase 2 Q9UIK4
DARPP-32 Protein phosphatase 1 regulatory subunit 1B Q9UD71 Y
DC-SIGN CD209 antigen Q9NNX6 Y
DC-SIGNR C-type lectin domain family 4 member M Q9H2X3 Y
DEAD-box protein 19B ATP-dependent RNA helicase DDX19B Q9UMR2 Y
Dectin-1 C-type lectin domain family 7 member A Q9BXN2
Desmoglein-1 Desmoglein-1 Q02413 Y
Discoidin domain receptor 1 Epithelial discoidin domain-containing receptor 1 Q08345
Discoidin domain receptor 2 Discoidin domain-containing receptor 2 Q16832
Dkk-1 Dickkopf-related protein 1 O94907 Y
Dkk-3 Dickkopf-related protein 3 Q9UBP4
Dkk-4 Dickkopf-related protein 4 Q9UBT3 Y
DLC8 Dynein light chain 1, cytoplasmic P63167
DLL4 Delta-like protein 4 Q9NR61 Y
DLRB1 Dynein light chain roadblock-type 1 Q9NP97
DMP1 Dentin matrix acidic phosphoprotein 1 Q13316
dopa decarboxylase Aromatic-L-amino-acid decarboxylase P20711 Y
DPP2 Dipeptidyl-peptidase 2 Q9UHL4
DRG-1 Vacuolar protein sorting-associated protein VTA1 homolog Q9NP79 Y
DRR1 Protein FAM107A O95990 Y
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Dtk Tyrosine-protein kinase receptor TYRO3 Q06418 Y
DYRK3 Dual specificity tyrosine-phosphorylation-regulated kinase 3 O43781
ECM1 Extracellular matrix protein 1 Q16610 Y
EDA Ectodysplasin-A (splice variant A2) Q92838 Y
EDAR Tumor necrosis factor receptor superfamily member EDAR Q9UNE0 Y
EF-1-β Elongation factor 1-beta P24534
EF-1-γ Elongation factor 1-gamma P26641
EG-VEGF Prokineticin-1 P58294 Y
eIF-4H Eukaryotic translation initiation factor 4H Q15056
eIF-5 Eukaryotic translation initiation factor 5 P55010 Y
eIF-5A-1 Eukaryotic translation initiation factor 5A-1 P63241
Elastase Leukocyte elastase P08246 Y
EMAP-2 Endothelial monocyte-activating polypeptide 2 Q12904 Y
EMMPRIN Basigin P35613
ENA-78 C-X-C motif chemokine 5 P42830 Y
Endocan cDNA FLJ50870, moderately similar to Endothelial cell-specific 
molecule 1
Q3V4E3
Endostatin Endostatin P39060 Y
Endothelin-converting enzyme 1 Endothelin-converting enzyme 1 P42892
Enterokinase Enteropeptidase P98073 Y
Eotaxin Eotaxin P51671 Y
Eotaxin-2 Small-inducible cytokine A24 O00175 Y
EphA1 Ephrin type-A receptor 1 P21709 Y
EPHA3 Ephrin type-A receptor 3 P29320 Y
EphA5 Ephrin type-A receptor 5 P54756
EphB4 Ephrin type-B receptor 4 P54760
Ephrin-A4 Ephrin-A4 P52798 Y
Ephrin-A5 Ephrin-A5 P52803 Y
Ephrin-B3 Ephrin-B3 Q15768 Y
Epithelial cell kinase Ephrin type-A receptor 2 P29317 Y
EPO-R Erythropoietin receptor P19235 Y
ER Estrogen receptor P03372 Y
ERBB1 Epidermal growth factor receptor P00533 Y
ERBB2 Receptor tyrosine-protein kinase erbB-2 P04626 Y
ERBB3 Receptor tyrosine-protein kinase erbB-3 P21860 Y
ERBB4 Receptor tyrosine-protein kinase erbB-4 Q15303 Y
Erythropoietin Erythropoietin P01588 Y
ESAM Endothelial cell-selective adhesion molecule Q96AP7 Y
ETHE1 Protein ETHE1, mitochondrial O95571
Factor B Complement factor B P00751 Y
Factor D Complement factor D P00746 Y
Factor H Complement factor H P08603 Y
Factor I Complement factor I P05156 Y
Fas ligand, soluble Tumor necrosis factor ligand superfamily member 6 P48023 Y
FCγ2A Low affinity immunoglobulin gamma Fc region receptor II-a P12318 Y
FCγ2B Low affinity immunoglobulin gamma Fc region receptor II-b P31994 Y
FCγ3B Low affinity immunoglobulin gamma Fc region receptor III-B O75015
FCγR1 High affinity immunoglobulin gamma Fc receptor I P12314 Y
Ferritin Ferritin heavy and light chains P02794, P02792 Y
Fetuin B Fetuin-B Q9UGM5 Y
FGF-4 Fibroblast growth factor 4 P08620
FGF-5 Fibroblast growth factor 5 P12034 Y
FGF-6 Fibroblast growth factor 6 P10767 Y
FGF-7 Keratinocyte growth factor P21781 Y
FGF-8B Fibroblast growth factor 8 - isoform 8B P55075 Y
FGF-9 Glia-activating factor P31371 Y
FGF-10 Fibroblast growth factor 10 O15520 Y
FGF-16 Fibroblast growth factor 16 O43320 Y
FGF-17 Fibroblast growth factor 17 O60258 Y
FGF-18 Fibroblast growth factor 18 O76093 Y
FGF-19 Fibroblast growth factor 19 O95750 Y
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FGF-20 Fibroblast growth factor 20 Q9NP95 Y
FGF-23 Fibroblast growth factor 23 Q9GZV9 Y
FGFR-2 Fibroblast growth factor receptor 2 P21802
FGFR-3 Fibroblast growth factor receptor 3 P22607
FGR Proto-oncogene tyrosine-protein kinase FGR P09769
Fibrinogen Fibrinogen alpha, beta, and gamma chains P02671, P02675, P02679 Y
Fibronectin Fibronectin P02751 Y
Fibronectin FN1.3 Fibronectin-1 Fragment 3 P02751 Y
Fibronectin FN1.4 Fibronectin-1 Fragment 4 P02751 Y
Ficolin-1 Ficolin-1 O00602
Ficolin-2 Ficolin-2 Q15485 Y
Ficolin-3 Ficolin-3 O75636
Flt-3 FL cytokine receptor P36888 Y
Flt-3 ligand SL cytokine P49771 Y
Follistatin Follistatin P19883 Y
Fortilin Translationally-controlled tumor protein P13693
Fractalkine/CX3CL-1 Fractalkine P78423 Y
FRP-1, soluble Secreted frizzled-related protein 1 Q8N474 Y
FRP-3, soluble Secreted frizzled-related protein 3 Q92765 Y
FSH Glycoprotein hormones alpha chain and Follitropin subunit beta P01215, P01225 Y
FSTL3 Follistatin-related protein 3 O95633 Y
FYN Proto-oncogene tyrosine-protein kinase Fyn P06241 Y
GA733-1 protein Tumor-associated calcium signal transducer 2 P09758 Y
Galectin-2 Galectin-2 P05162 Y
Galectin-3 Galectin-3 P17931 Y
Galectin-4 Galectin-4 P56470 Y
GAPDH Glyceraldehyde-3-phosphate dehydrogenase P04406
Gas1 Growth arrest-specific protein 1 P54826 Y
GASP-1 WAP, kazal, immunoglobulin, kunitz and NTR domain-containing 
protein 2
Q8TEU8 Y
GASP-2 G-protein coupled receptor-associated sorting protein 2 Q96D09 Y
Gastrin-releasing peptide Gastrin-releasing peptide P07492
GCP-2 C-X-C motif chemokine 6 P80162 Y
G-CSF-R Granulocyte colony-stimulating factor receptor Q99062 Y
GDF-11 Growth/differentiation factor 11 O95390 Y
GDF-9 Growth/differentiation factor 9 O60383 Y
GDNF Glial cell line-derived neurotrophic factor P39905 Y
GFAP Glial fibrillary acidic protein P14136 Y
GFR α-1 GDNF family receptor alpha-1 P56159 Y
GFR α-2 GDNF family receptor alpha-2 O00451 Y
GFR α-3 GDNF family receptor alpha-3 O60609 Y
Glucocorticoid receptor Glucocorticoid receptor P04150 Y
Glutamate carboxypeptidase Cytosolic non-specific dipeptidase Q96KP4 Y
Glycoprotein VI Platelet glycoprotein VI Q9HCN6 Y
Glypican 2 Glypican-2 Q8N158 Y
Glypican 3 Glypican-3 P51654 Y
GNS N-acetylglucosamine-6-sulfatase P15586
gp130, soluble Interleukin-6 receptor subunit beta P40189 Y
GPIIbIIIa Integrin alpha-Iib and Integrin beta-3 P08514,P05106
Granulysin Granulysin P22749
Granzyme A Granzyme A P12544 Y
Granzyme B Granzyme B P10144 Y
Granzyme H Granzyme H P20718 Y
Group IB phospholipase A2 Phospholipase A2 P04054 Y
Group IIA phospholipase A2 Phospholipase A2, membrane associated P14555 Y
Group IIE phospholipase A2 Group IIE secretory phospholipase A2 Q9NZK7 Y
Group V phospholipase A2 Calcium-dependent phospholipase A2 P39877 Y
Group X phospholipase A2 Group 10 secretory phospholipase A2 O15496 Y
Growth hormone receptor Growth hormone receptor P10912 Y
Gro-α Growth-regulated alpha protein P09341 Y
Gro-β Macrophage inflammatory protein 2-alpha P19875
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Gro-γ Macrophage inflammatory protein 2-beta P19876 Y
GSK-3 α Glycogen synthase kinase-3 alpha P49840 Y
GSK-3 β Glycogen synthase kinase-3 beta P49841 Y
HAI-1 Kunitz-type protease inhibitor 1 O43278 Y
HAI-2 Kunitz-type protease inhibitor 2 O43291
HAPLN1 Hyaluronan and proteoglycan link protein 1 P10915 Y
Haptoglobin, Mixed Type Haptoglobin P00738 Y
Hat1 Histone acetyltransferase type B catalytic subunit O14929 Y
HB-EGF Heparin-binding EGF-like growth factor Q99075 Y
HCC-1 C-C motif chemokine 14 Q16627 Y
HCC-4 Small-inducible cytokine A16 O15467 Y
HCK Tyrosine-protein kinase HCK P08631 Y
HDAC8 Histone deacetylase 8 Q9BY41 Y
HE4 WAP four-disulfide core domain protein 2 Q14508 Y
Heme oxygenase 2 Heme oxygenase 2 P30519 Y
Hemopexin Hemopexin P02790 Y
Heparin cofactor II Heparin cofactor 2 P05546 Y
Hepcidin-25 Hepcidin P81172 Y
HGF Hepatocyte growth factor P14210 Y
HGF activator Hepatocyte growth factor activator Q04756
HGF R Hepatocyte growth factor receptor P08581 Y
HINT1 Histidine triad nucleotide-binding protein 1 P49773
HIPK3 Homeodomain-interacting protein kinase 3 Q9H422 Y
Histone H1.2 Histone H1.2 P16403 Y
Histone H2A.z Histone H2A.Z P0C0S5
HIV-2 Rev Protein Rev (Human Immunodeficiency Virus) P18093 Y
HMG-1 High mobility group protein B1 P09429 Y
HMTase G9a Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 Q96KQ7 Y
HPV E7 Type 16 Protein E7 (Human Papillomavirus Type 16) P03129 Y
HPV E7 Type 18 Protein E7 (Human Papillomavirus Type 18) P06788 Y
HSP 40 DnaJ homolog subfamily B member 1 P25685
HSP 60 60 kDa heat shock protein, mitochondrial P10809 Y
HSP 70 Heat shock 70 kDa protein 1 P08107
HSP 90α Heat shock protein HSP 90-alpha P07900 Y
HSP 90β Heat shock protein HSP 90-beta P08238 Y
HTRA2 Serine protease HTRA2, mitochondrial O43464 Y
iC3b Complement C3b, incactivated P01024 Y
ICOS Inducible T-cell co-stimulator Q9Y6W8 Y
IDUA Alpha-L-iduronidase P35475 Y
Iduronate 2-sulfatase Iduronate 2-sulfatase P22304 Y
IFN-αA Interferon alpha-2 P01563 Y
IFN-γ Interferon gamma P01579 Y
IFN-γ R1 Interferon-gamma receptor alpha chain P15260
IFN-λ 1 Interleukin-29 Q8IU54 Y
IFN-λ 2 Interleukin-28A Q8IZJ0 Y
IgE Immunoglobulin E Y
IGFBP-1 Insulin-like growth factor-binding protein 1 P08833 Y
IGFBP-2 Insulin-like growth factor-binding protein 2 P18065 Y
IGFBP-3 Insulin-like growth factor-binding protein 3 P17936 Y
IGFBP-4 Insulin-like growth factor-binding protein 4 P22692 Y
IGFBP-5 Insulin-like growth factor-binding protein 5 P24593 Y
IGFBP-6 Insulin-like growth factor-binding protein 6 P24592 Y
IGFBP-7 Insulin-like growth factor-binding protein 7 Q16270 Y
IGF-I Insulin-like growth factor IA and IB P01343, P05019 Y
IGF-II receptor Cation-independent mannose-6-phosphate receptor P11717 Y
IgG Immunoglobulin G
IgM Immunoglobulin M Y
IL-1β Interleukin-1 beta P01584 Y
IL-1 F7 Interleukin-1 family member 7 Q9NZH6 Y
IL-1 R AcP Interleukin-1 receptor accessory protein Q9NPH3 Y
IL-1 R4 Interleukin-1 receptor-like 1 Q01638
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
10
.4
53
8.
1 
: P
os
te
d 
14
 J
un
 2
01
0
Target Uni-Prot Protein Name Uni-Prot Acc # CKD
IL-1 Rrp2 Interleukin-1 receptor-like 2 Q9HB29 Y
IL-1 sRI Interleukin-1 receptor type I P14778 Y
IL-2 Interleukin-2 P60568 Y
IL-2 sRα Interleukin-2 receptor alpha chain P01589
IL-2 sRγ Cytokine receptor common gamma chain P31785 Y
IL-4 Interleukin-4 P05112 Y
IL-4 sR Interleukin-4 receptor alpha chain P24394 Y
IL-5 Interleukin-5 P05113
IL-6 Interleukin-6 P05231 Y
IL-6 sRα Interleukin-6 receptor alpha chain P08887 Y
IL-7 Interleukin-7 P13232 Y
IL-7 Rα Interleukin-7 receptor alpha chain P16871 Y
IL-8 Interleukin-8 P10145 Y
IL-9 Interleukin-9 P15248 Y
IL-10 Interleukin-10 P22301 Y
IL-10 Rβ Interleukin-10 receptor beta chain Q08334 Y
IL-11 Interleukin-11 P20809 Y
IL-11 Rα Interleukin-11 receptor alpha chain Q14626
IL-12 Interleukin-12 subunits alpha and beta P29459, P29460
IL-12 Rβ1 Interleukin-12 receptor beta-1 chain P42701 Y
IL-12 Rβ2 Interleukin-12 receptor beta-2 chain Q99665 Y
IL-13 Interleukin-13 P35225 Y
IL-13 Rα1 Interleukin-13 receptor alpha-1 chain P78552 Y
IL-15 Rα Interleukin-15 receptor alpha chain Q13261 Y
IL-16 Interleukin-16 Q14005 Y
IL-17 Interleukin-17A Q16552 Y
IL-17B Interleukin-17B Q9UHF5 Y
IL-17D Interleukin-17D Q8TAD2 Y
IL-17E Interleukin-25 Q9H293 Y
IL-17F Interleukin-17F Q96PD4 Y
IL-17 RC Interleukin-17 receptor C Q8NAC3
IL-17 RD Interleukin-17 receptor D Q8NFM7 Y
IL-17 sR Interleukin-17 receptor A Q96F46 Y
IL-18 BPa Interleukin-18-binding protein O95998 Y
IL-18 Rα Interleukin-18 receptor 1 Q13478 Y
IL-18 Rβ Interleukin-18 receptor accessory protein O95256 Y
IL-19 Interleukin-19 Q9UHD0 Y
IL-20 Interleukin-20 Q9NYY1 Y
IL-22 Interleukin-22 Q9GZX6 Y
IL-22 Rα1 Interleukin-22 receptor subunit alpha-1 Q8N6P7
IL-24 Interleukin-24 Q13007 Y
IL-27 Interleukin 27 Q8NEV9 Y
Importin β1 Importin subunit beta-1 Q14974
ING1 Inhibitor of growth protein 1 Q9UK53
Insulysin Insulin-degrading enzyme P14735 Y
Integrin α1β1 Integrin alpha-1 and Integrin beta-1 P56199, P05556 Y
IP-10 Small-inducible cytokine B10 P02778 Y
IR Insulin receptor P06213 Y
I-TAC Small-inducible cytokine B11 O14625 Y
ICAM-1, soluble Intercellular adhesion molecule 1 P05362
ICAM-2, soluble Intercellular adhesion molecule 2 P13598 Y
ICAM-3, soluble Intercellular adhesion molecule 3 P32942 Y
JAM-B Junctional adhesion molecule B P57087 Y
JAM-C Junctional adhesion molecule C Q9BX67 Y
Kallikrein 4 Kallikrein-4 Q9Y5K2 Y
Kallikrein 5 Kallikrein-5 Q9Y337 Y
Kallikrein 6 Kallikrein-6 Q92876 Y
Kallikrein 7 Kallikrein-7 P49862 Y
Kallikrein 8 Neuropsin O60259 Y
Kallikrein 11 Kallikrein-11 Q9UBX7
Kallikrein 12 Kallikrein-12 Q9UKR0 Y
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Kallikrein 13 Kallikrein-13 Q9UKR3 Y
Kallikrein 14 Kallikrein-14 Q9P0G3
Kallistatin Kallistatin P29622 Y
Karyopherin-α2 Importin subunit alpha-2 P52292 Y
Kininogen, HMW, Single Chain Kininogen-1 (single chain form) P01042 Y
Kininogen, HMW, Two Chain Kininogen-1 (two-chain form) P01042 Y
Kremen2 Kremen protein 2 Q8NCW0 Y
Ku70 ATP-dependent DNA helicase 2 subunit 1 P12956 Y
Lactoferrin Lactotransferrin P02788 Y
LAG-1 Macrophage inflammatory protein-1b2 Q8NHW4 Y
Lamin-B1 Lamin-B1 P20700
Laminin Laminin subunits alpha-1, beta-1, and gamma-1 P25391, P07942, P11047 Y
Langerin C-type lectin domain family 4 member K Q9UJ71 Y
Layilin Layilin Q6UX15 Y
LBP Lipopolysaccharide-binding protein P18428 Y
LCK Proto-oncogene tyrosine-protein kinase LCK P06239 Y
LD78-β Small-inducible cytokine A3-like 1 P16619 Y
LDH-H 1 L-lactate dehydrogenase B chain P07195
Legumain Legumain Q99538
Leptin Leptin P41159 Y
Lipocalin 2 Neutrophil gelatinase-associated lipocalin P80188 Y
LOX-1 Oxidized low-density lipoprotein receptor 1 P78380 Y
LRIG3 Leucine-rich repeats and immunoglobulin-like domains protein 3 Q6UXM1 Y
LRPAP Alpha-2-macroglobulin receptor-associated protein P30533 Y
LSAMP Limbic system-associated membrane protein Q13449 Y
LTA-4 hydrolase Leukotriene A-4 hydrolase P09960
Luteinizing hormone Glycoprotein hormones alpha chain and Lutropin subunit beta P01215, P01229 Y
LY9 T-lymphocyte surface antigen Ly-9 Q9HBG7 Y
Lymphotactin Lymphotactin P47992 Y
Lymphotoxin α1/β2 Lymphotoxin-alpha (1) and Lymphotoxin-beta (2) P01374, Q06643 Y
Lymphotoxin α2/β1 Lymphotoxin-alpha (2) and Lymphotoxin-beta (1) P01374, Q06643 Y
Lymphotoxin β R Tumor necrosis factor receptor superfamily member 3 P36941 Y
LYN A Tyrosine-protein kinase Lyn P07948 Y
LYN B Tyrosine-protein kinase Lyn, isoform B P07948-2 Y
Lysozyme Lysozyme C P61626 Y
LYVE-1 Lymphatic vessel endothelial hyaluronic acid receptor 1 Q9Y5Y7 Y
Macrophage mannose receptor Macrophage mannose receptor 1 P22897 Y
Macrophage scavenger receptor Macrophage scavenger receptor types I and II P21757
MAP2K2 Dual specificity mitogen-activated protein kinase kinase 2 P36507
MAPK1 Mitogen-activated protein kinase 1 P28482 Y
MAPK12 Mitogen-activated protein kinase 12 P53778
MAPK13 Mitogen-activated protein kinase 13 O15264 Y
MAPK14 Mitogen-activated protein kinase 14 Q16539 Y
MAPK3 Mitogen-activated protein kinase 3 P27361 Y
MAPK8 Mitogen-activated protein kinase 8 P45983
MAPKAPK2 MAP kinase-activated protein kinase 2 P49137
MAPKAPK3 MAP kinase-activated protein kinase 3 Q16644
MAPKAPK5 MAP kinase-activated protein kinase 5 Q8IW41
Marapsin Serine protease 27 Q9BQR3
MASP3 Complement-activating component of Ra-reactive factor splice 
variant MASP3
Q96RS4
MATK Megakaryocyte-associated tyrosine-protein kinase P42679 Y
Matrilin-2 Matrilin-2 O00339 Y
Matrilin-3 Matrilin-3 O15232 Y
MBD4 Methyl-CpG-binding domain protein 4 O95243
MBL Mannose-binding protein C P11226 Y
MCM2 DNA replication licensing factor MCM2 P49736
MCP-1 Small-inducible cytokine A2 P13500 Y
MCP-2 Small-inducible cytokine A8 P80075 Y
MCP-3 Small-inducible cytokine A7 P80098 Y
MCP-4 Small-inducible cytokine A13 Q99616 Y
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M-CSF Macrophage colony-stimulating factor 1 P09603
M-CSF R Macrophage colony-stimulating factor 1 receptor P07333 Y
MD-1 Lymphocyte antigen 86 O95711 Y
MDC Small-inducible cytokine A22 O00626 Y
MDHC Malate dehydrogenase, cytoplasmic P40925
Mediator complex subunit 1 Mediator of RNA polymerase II transcription subunit 1 Q15648
MEK1 Dual specificity mitogen-activated protein kinase kinase 1 Q02750 Y
MEPE Matrix extracellular phosphoglycoprotein Q9NQ76 Y
Mesothelin Mesothelin Q13421
MetAP 1 Methionine aminopeptidase 1 P53582 Y
MetAP2 Methionine aminopeptidase 2 P50579
MFRP Membrane frizzled-related protein Q9BY79
MIA Melanoma-derived growth regulatory protein Q16674 Y
MICA MHC class I chain-related protein A Q29983 Y
Midkine Midkine P21741 Y
MIG Small-inducible cytokine B9 Q07325 Y
MIP-1α C-C motif chemokine 3 P10147 Y
MIP-1β Small-inducible cytokine A4 P13236 Y
MIP-3α Small-inducible cytokine A20 P78556 Y
MIP-3β Small-inducible cytokine A19 Q99731 Y
MIP-4 C-C motif chemokine 18 P55774 Y
MIP-5 C-C motif chemokine 15 Q16663 Y
MMP-2 72 kDa type IV collagenase P08253
MMP-3 Stromelysin-1 P08254
MMP-7 Matrilysin P09237 Y
MMP-8 Neutrophil collagenase P22894 Y
MMP-9 Matrix metalloproteinase-9 P14780 Y
MMP-10 Stromelysin-2 P09238 Y
MMP-17 Matrix metalloproteinase-17 Q9ULZ9
MOZ Histone acetyltransferase MYST3 Q92794 Y
MPIF-1 C-C motif chemokine 23 P55773 Y
MRC2 Macrophage mannose receptor 2 Q9UBG0 Y
MRCKβ Serine/threonine-protein kinase MRCK beta Q9Y5S2
MSP R Macrophage-stimulating protein receptor Q04912 Y
Myeloperoxidase Myeloperoxidase P05164 Y
Myoglobin Myoglobin P02144 Y
Myosin regulatory light chain 2 Myosin regulatory light chain 2, ventricular/cardiac muscle isoform P10916 Y
NACα Nascent polypeptide-associated complex subunit alpha Q13765
NADPH-P450 Oxidoreductase NADPH--cytochrome P450 reductase P16435 Y
NAGK N-acetyl-D-glucosamine kinase Q9UJ70
NANOG Homeobox protein NANOG Q9H9S0 Y
NAP-2 Neutrophil-activating peptide 2 P02775 Y
Nectin-like protein 1 Cell adhesion molecule 3 Q8N126
Nectin-like protein 2 Cell adhesion molecule 1 Q9BY67 Y
Neprilysin-2 Membrane metallo-endopeptidase-like 1 Q495T6
Netrin-4 Netrin-4 Q9HB63 Y
NEUREGULIN-1 Neuregulin-1 Q02297 Y
Neurotrophin-3 Neurotrophin-3 P20783 Y
Neurotrophin-5 Neurotrophin-5 P34130 Y
Nidogen Nidogen-1 P14543 Y
Nidogen-2 Nidogen-2 Q14112
NKG2D NKG2-D type II integral membrane protein P26718 Y
NKp30 Natural cytotoxicity triggering receptor 3 O14931 Y
NKp44 Natural cytotoxicity triggering receptor 2 O95944 Y
Noggin Noggin Q13253 Y
Nogo Receptor Reticulon-4 receptor Q9BZR6 Y
NovH Protein NOV homolog P48745 Y
NRP1 Neuropilin-1 O14786 Y
OBCAM Opioid-binding protein/cell adhesion molecule Q14982
OCIAD1 OCIA domain-containing protein 1 Q9NX40
Oncostatin M Oncostatin-M P13725 Y
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RUNX-2 Runt-related transcription factor 2 Q13950 Y
Osteonectin SPARC P09486 Y
Osteoprotegerin Tumor necrosis factor receptor superfamily member 11B O00300 Y
Otubain-1 Ubiquitin thioesterase OTUB1 Q96FW1
OX40 Ligand Tumor necrosis factor ligand superfamily member 4 P23510 Y
p27Kip1 Cyclin-dependent kinase inhibitor 1B P46527
PAFAH β subunit Platelet-activating factor acetylhydrolase IB subunit beta P68402 Y
PAI-1 Plasminogen activator inhibitor 1 P05121 Y
PAK3 Serine/threonine-protein kinase PAK 3 O75914 Y
PAK6 Serine/threonine-protein kinase PAK 6 Q9NQU5
PAK7 Serine/threonine-protein kinase PAK 7 Q9P286 Y
PAPP-A Pappalysin-1 Q13219 Y
P-Cadherin Cadherin-3 P22223 Y
PCNA Proliferating cell nuclear antigen P12004 Y
PDGF Rβ Beta-type platelet-derived growth factor receptor P09619 Y
PDGF-AA Platelet-derived growth factor A chain P04085 Y
PDGF-BB Platelet-derived growth factor B chain P01127 Y
PDGF-CC Platelet-derived growth factor C chain Q9NRA1
PD-L2 Programmed cell death 1 ligand 2 Q9BQ51 Y
PDPK1 3-phosphoinositide-dependent protein kinase 1 O15530 Y
PECAM-1 Platelet endothelial cell adhesion molecule P16284 Y
Peptide YY Peptide YY P10082
Peroxiredoxin-1 Peroxiredoxin-1 Q06830
Persephin Persephin O60542 Y
PF-4 Platelet factor 4 P02776 Y
PGRP-S Peptidoglycan recognition protein O75594 Y
Phosphoglycerate mutase 1 Phosphoglycerate mutase 1 P18669
pIgR Polymeric immunoglobulin receptor P01833 Y
PIK3Cα/PIK3R1 Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit 
alpha isoform, Phosphatidylinositol 3-kinase regulatory subunit 
alpha Complex
P42336, P27986 Y
PK3CG Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit 
gamma isoform
P48736 Y
PKB RAC-alpha serine/threonine-protein kinase P31749 Y
PKB γ RAC-gamma serine/threonine-protein kinase Q9Y243 Y
PKC-α Protein kinase C alpha type P17252 Y
PKC-β-II Protein kinase C beta type (splice variant Beta-II) P05771 Y
PKC-γ Protein kinase C gamma type P05129
PKC-δ Protein kinase C delta type Q05655 Y
PKC-ζ Protein kinase C zeta type Q05513 Y
Plasmin Plasmin heavy chain A and light chain B P00747 Y
Plasminogen Plasminogen P00747 Y
Pleiotrophin Pleiotrophin P21246 Y
PLGF Placenta growth factor P49763 Y
PLK-1 Serine/threonine-protein kinase PLK1 P53350 Y
PLPP Pyridoxal phosphate phosphatase Q96GD0
PPAC Low molecular weight phosphotyrosine protein phosphatase P24666
Prekallikrein Plasma kallikrein (precursor) P03952 Y
PRKA C-α cAMP-dependent protein kinase catalytic subunit alpha P17612 Y
PRKCI Protein kinase C iota type P41743 Y
PRKCQ Protein kinase C theta type Q04759
PRL Prolactin P01236 Y
Properdin Properdin P27918 Y
Protease nexin I Glia-derived nexin P07093 Y
Proteasome subunit p40 26S proteasome non-ATPase regulatory subunit 7 P51665
Proteasome subunit α1 Proteasome subunit alpha type-1 P25786
Proteasome subunit α6 Proteasome subunit alpha type-6 P60900
Protein C Vitamin K-dependent protein C P04070 Y
Protein C Inhibitor Plasma serine protease inhibitor P05154 Y
Protein S Vitamin K-dependent protein S P07225 Y
Proteinase-3 Myeloblastin P24158 Y
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Prothrombin Prothrombin P00734 Y
PSA Prostate-specific antigen P07288 Y
PSA-ACT Prostate-specific antigen and Alpha-1-antichymotrypsin P07288, P01011 Y
P-Selectin P-selectin P16109 Y
PSMA Glutamate carboxypeptidase 2 Q04609
pTEN Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual-
specificity protein phosphatase PTEN
P60484 Y
PTH Parathyroid hormone P01270
PTHrP Parathyroid hormone-related protein P12272 Y
PTK6 Tyrosine-protein kinase 6 Q13882
PTP-1B Tyrosine-protein phosphatase non-receptor type 1 P18031 Y
Rab GDP dissociation inhibitor β Rab GDP dissociation inhibitor beta P50395 Y
RAC1 Ras-related C3 botulinum toxin substrate 1 P63000 Y
RACK1 Guanine nucleotide-binding protein subunit beta-2-like 1 P63244
RAD51 DNA repair protein RAD51 homolog 1 Q06609 Y
RANTES Small-inducible cytokine A5 P13501 Y
RBP Retinol-binding protein 4 P02753
RELT Tumor necrosis factor receptor superfamily member 19L Q969Z4 Y
Renin Renin P00797 Y
resistin Resistin Q9HD89 Y
RET Proto-oncogene tyrosine-protein kinase receptor ret P07949 Y
RGM-A Repulsive guidance molecule A Q96B86
RGM-B RGM domain family member B Q6NW40
RGM-C Hemojuvelin Q6ZVN8 Y
RNAbp 39 RNA-binding protein 39 Q14498
ROR1 Tyrosine-protein kinase transmembrane receptor ROR1 Q01973 Y
RPS6Kα3 Ribosomal protein S6 kinase alpha-3 P51812 Y
RS3A 40S ribosomal protein S3a P61247
RS7 40S ribosomal protein S7 P62081
RSK-like protein kinase Ribosomal protein S6 kinase alpha-5 O75582
S100A12 Protein S100-A12 P80511
SAA Serum amyloid A protein P02735
SAP Serum amyloid P-component P02743 Y
SBDS Ribosome maturation protein SBDS Q9Y3A5
SCF sR Mast/stem cell growth factor receptor P10721 Y
SCGF-α C-type lectin domain family 11 member A (alpha form) Q9Y240 Y
SCGF-β C-type lectin domain family 11 member A (beta form) Q9Y240 Y
SDF-1α SDF-1-alpha P48061 Y
SDF-1β SDF-1-beta P48061 Y
Secretin Secretin P09683
Semaphorin 3A Semaphorin-3A Q14563
sE-Selectin E-selectin P16581 Y
SET9 Histone-lysine N-methyltransferase, H3 lysine-4 specific SET7 Q8WTS6 Y
SEZ6L2 Seizure 6-like protein 2 Q6UXD5
SGTα Small glutamine-rich tetratricopeptide repeat-containing protein 
alpha
O43765
SHP-2 Tyrosine-protein phosphatase non-receptor type 11 Q06124 Y
Siglec-3 Myeloid cell surface antigen CD33 P20138
Siglec-6 Sialic acid-binding Ig-like lectin 6 O43699 Y
Siglec-7 Sialic acid-binding Ig-like lectin 7 Q9Y286 Y
Siglec-9 Sialic acid-binding Ig-like lectin 9 Q9Y336 Y
SKP1 S-phase kinase-associated protein 1 P63208
SLAMF5 SLAM family member 5 Q9UIB8
SLITRK1 SLIT and NTRK-like protein 1 Q96PX8
SLPI Antileukoproteinase P03973 Y
sL-Selectin L-selectin P14151 Y
SMAC/Diablo Diablo homolog, mitochondrial Q9NR28 Y
SOD1 Superoxide dismutase [Cu-Zn] P00441 Y
Soggy-1 Dickkopf-like protein 1 Q9UK85 Y
Somatostatin-28 Somatostatin-28 P61278
Sonic Hedgehog Sonic hedgehog protein Q15465 Y
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Sorting nexin 4 Sorting nexin-4 O95219
sRAGE Advanced glycosylation end product-specific receptor Q15109
sRANKL Tumor necrosis factor ligand superfamily member 11 O14788 Y
SRCN1 V-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog 
(Avian)
Q76P87
Stabilin-2 Stabilin-2 Q8WWQ8 Y
sTie-1 Tyrosine-protein kinase receptor Tie-1 P35590 Y
sTie-2 Angiopoietin-1 receptor Q02763 Y
STK16 Serine/threonine-protein kinase 16 O75716 Y
Stress-induced-phosphoprotein 1 Stress-induced-phosphoprotein 1 P31948
suPAR Urokinase plasminogen activator surface receptor Q03405 Y
Survivin Baculoviral IAP repeat-containing protein 5 O15392 Y
Syntaxin 1A Syntaxin-1A Q16623 Y
TACI Tumor necrosis factor receptor superfamily member 13B O14836 Y
TAFI Carboxypeptidase B2 Q96IY4
TARC Small-inducible cytokine A17 Q92583
tau Microtubule-associated protein tau P10636 Y
TBK1 Serine/threonine-protein kinase TBK1 Q9UHD2 Y
TBP TATA-box-binding protein P20226 Y
TCPTP Tyrosine-protein phosphatase non-receptor type 2 P17706 Y
TEC Tyrosine-protein kinase Tec P42680
TECK Small-inducible cytokine A25 O15444 Y
Tenascin Tenascin P24821 Y
Testican-1 Testican-1 Q08629
Testican-2 Testican-2 Q92563 Y
TFPI Tissue factor pathway inhibitor P10646 Y
TGF-β1 Transforming growth factor beta-1 P01137 Y
TGF-β2 Transforming growth factor beta-2 P61812 Y
TGF-β3 Transforming growth factor beta-3 P10600 Y
TGF-β R III TGF-beta receptor type III Q03167 Y
Thrombin Thrombin heavy and light chains P00734 Y
Thrombopoietin Thrombopoietin P40225 Y
Thrombopoietin Receptor Thrombopoietin receptor P40238
Thrombospondin-1 Thrombospondin-1 P07996 Y
Thrombospondin-2 Thrombospondin-2 P35442
Thrombospondin-4 Thrombospondin-4 P35443 Y
Thyroglobulin Thyroglobulin P01266
Thyroid peroxidase Thyroid peroxidase P07202
Thyroxine-Binding Globulin Thyroxine-binding globulin P05543 Y
TIMP-1 Metalloproteinase inhibitor 1 P01033 Y
TIMP-2 Metalloproteinase inhibitor 2 P16035 Y
TIMP-3 Metalloproteinase inhibitor 3 P35625 Y
TLR2 Toll-like receptor 2 O60603
TLR4 Toll-like receptor 4 O00206
TNF sR-I Tumor necrosis factor receptor superfamily member 1A P19438 Y
TNF sR-II Tumor necrosis factor receptor superfamily member 1B P20333 Y
TNFSF15 Tumor necrosis factor ligand superfamily member 15 O95150 Y
TNFSF18 Tumor necrosis factor ligand superfamily member 18 Q9UNG2 Y
TNR4 Tumor necrosis factor receptor superfamily member 4 P43489
Topoisomerase I DNA topoisomerase 1 P11387 Y
tPA Tissue-type plasminogen activator P00750 Y
TRAIL R4 Tumor necrosis factor receptor superfamily member 10D Q9UBN6 Y
Transferrin Serotransferrin P02787
TrATPase Tartrate-resistant acid phosphatase type 5 P13686 Y
TrkA High affinity nerve growth factor receptor P04629 Y
TrkC NT-3 growth factor receptor Q16288 Y
Troponin I Troponin I, cardiac muscle P19429 Y
Troponin T Troponin T, cardiac muscle P45379 Y
Trypsin Trypsin-1 P07477 Y
Trypsin 3 Trypsin-3 P35030 Y
Tryptase β-2 Tryptase beta-2 P20231 Y
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Tryptase γ Tryptase gamma Q9NRR2 Y
TSH Glycoprotein hormones alpha and Thyrotropin subunit beta chains P01215, P01222 Y
TSLP Thymic stromal lymphopoietin Q969D9 Y
TSLP R Thymic stromal lymphopoietin protein receptor Q9HC73 Y
TWEAK Tumor necrosis factor ligand superfamily member 12 O43508 Y
UB2L3 Ubiquitin-conjugating enzyme E2 L3 P68036
UBC9 SUMO-conjugating enzyme UBC9 P63279 Y
UBE2N Ubiquitin-conjugating enzyme E2 N P61088
Ubiquitin+1 Ubiquitin P62988 Y
UFC1 Ufm1-conjugating enzyme 1 Q9Y3C8 Y
UFM1 Ubiquitin-fold modifier 1 P61960
ULBP-1 NKG2D ligand 1 Q9BZM6 Y
ULBP-2 NKG2D ligand 2 Q9BZM5 Y
ULBP-3 NKG2D ligand 3 Q9BZM4 Y
uPA Urokinase-type plasminogen activator P00749 Y
URB Coiled-coil domain-containing protein 80 Q76M96 Y
Vasoactive Intestinal Peptide Vasoactive intestinal peptide P01282
VCAM-1 Vascular cell adhesion protein 1 P19320 Y
VEGF Vascular endothelial growth factor A P15692 Y
VEGF-C Vascular endothelial growth factor C P49767 Y
VEGF-D Vascular endothelial growth factor D O43915 Y
VEGF sR2 Vascular endothelial growth factor receptor 2 P35968 Y
VEGF sR3 Vascular endothelial growth factor receptor 3 P35916 Y
VHR Dual specificity protein phosphatase 3 P51452 Y
vWF von Willebrand factor P04275 Y
WIF-1 Wnt inhibitory factor 1 Q9Y5W5 Y
WISP-1 WNT1-inducible-signaling pathway protein 1 O95388 Y
WISP-3 WNT1-inducible-signaling pathway protein 3 O95389 Y
WNK3 Serine/threonine-protein kinase WNK3 Q9BYP7 Y
XEDAR Tumor necrosis factor receptor superfamily member 27 Q9HAV5 Y
X-Pro aminopeptidase 1 Xaa-Pro aminopeptidase 1 Q9NQW7 Y
YES Proto-oncogene tyrosine-protein kinase Yes P07947 Y
YKL-40 Chitinase-3-like protein 1 P36222
ZAP70 Tyrosine-protein kinase ZAP-70 P43403 Y
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LLOQ ULOQ log Range
α1-Antichymotrypsin 2.4E-13 9.1E-10 3.6
α1-Antitrypsin 1.6E-11 7.6E-08 3.7
α2-Antiplasmin 6.0E-13 5.0E-08 4.9
α2-HS-Glycoprotein 4.1E-13 1.8E-08 4.6
α2-Macroglobulin 3.5E-12 3.9E-08 4.0
Activated Protein C 7.3E-13 2.6E-09 3.6
Activin A 3.5E-13 4.2E-09 4.1
ADAMTS-4 4.8E-13 2.7E-10 2.8
Aggrecan 1.2E-12 2.0E-09 3.2
AIF-1 2.5E-12 8.1E-10 2.5
Albumin 4.9E-11 2.0E-08 2.6
Alkaline phosphatase, bone 8.0E-12 1.2E-08 3.2
ALT 4.3E-12 6.9E-09 3.2
amyloid precursor protein 2.6E-13 7.6E-10 3.5
Angiogenin 6.6E-13 1.1E-09 3.2
Angiopoietin-1 5.2E-11 6.9E-09 2.1
Angiopoietin-2 1.8E-13 1.2E-09 3.8
Angiopoietin-4 8.5E-13 2.9E-09 3.5
Angiostatin 1.5E-13 2.4E-09 4.2
Angiotensinogen 4.7E-12 5.5E-08 4.1
Apo A-I 2.0E-11 2.5E-08 3.1
Apo B 1.1E-12 4.5E-09 3.6
Apo E 3.5E-11 7.8E-09 2.4
Apo E2 1.8E-10 6.8E-09 1.6
Apo E3 1.9E-12 6.5E-10 2.5
Apo E4 9.1E-13 1.3E-09 3.2
Table 5. Limits of quantification
Concentration (M) (logRFU Fit)Target
APRIL 1.3E-10 5.1E-09 1.6
β2-Microglobulin 5.9E-13 1.8E-09 3.5
B7 1.9E-11 3.4E-08 3.3
BARK1 1.3E-13 5.5E-10 3.6
BCA-1 2.0E-13 2.7E-10 3.1
Bcl-2 1.0E-12 2.4E-09 3.4
BCL2A1 2.4E-13 7.8E-10 3.5
BDNF 1.4E-11 1.1E-08 2.9
βIGH3 1.5E-12 1.3E-09 2.9
BMP-1 9.1E-13 1.1E-09 3.1
BMP10 1.3E-10 3.4E-08 2.4
BMP-14 1.3E-12 2.4E-09 3.3
BMP-6 2.2E-12 7.5E-10 2.5
BMP-7 1.5E-12 1.3E-09 3.0
BMPR1A 1.6E-11 2.4E-08 3.2
Bone proteoglycan II 7.3E-12 1.6E-10 1.3
BPI 2.6E-13 4.6E-10 3.3
BTK 1.6E-13 2.0E-09 4.1
C1q 8.2E-13 2.9E-10 2.6
C1r 1.3E-13 1.6E-09 4.1
C1s 6.7E-12 1.6E-08 3.4
C2 5.4E-14 6.0E-10 4.0
C3 6.5E-13 8.4E-10 3.1
C3a 7.0E-11 2.4E-08 2.5
C3adesArg 4.2E-14 4.4E-10 4.0
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Concentration (M) (logRFU Fit)Target
C3b 6.5E-11 4.9E-09 1.9
C4 6.0E-14 4.6E-09 4.9
C4b 7.6E-12 7.8E-09 3.0
C5 4.3E-12 2.7E-09 2.8
C5a 3.4E-13 1.3E-09 3.6
C5b,6 Complex 2.4E-12 9.0E-10 2.6
C6 1.4E-12 4.6E-10 2.5
C7 5.6E-12 7.9E-09 3.2
C8 2.0E-11 4.2E-09 2.3
C9 2.6E-14 3.6E-10 4.1
Cadherin-1 1.8E-12 7.2E-09 3.6
Cadherin-12 4.3E-10 1.0E-06 3.4
Cadherin-2 4.0E-11 3.4E-08 2.9
Cadherin-5 3.9E-12 7.0E-09 3.3
Cadherin-6 2.3E-12 6.8E-09 3.5
Calpain I 7.0E-14 3.3E-10 3.7
CAMK1D 7.9E-11 6.1E-10 0.9
Carbonic anhydrase VI 5.6E-11 1.4E-08 2.4
Carbonic anhydrase IX 1.0E-06 1.0E-06 0.0
Cardiotrophin-1 1.4E-12 1.1E-09 2.9
Caspase-3 4.2E-13 3.2E-09 3.9
Catalase 7.8E-14 8.2E-10 4.0
Cathepsin A 5.4E-14 1.2E-09 4.3
Cathepsin B 5.8E-13 5.4E-10 3.0
Cathepsin G 5.9E-12 1.8E-09 2.5
Cathepsin H 8.0E-13 2.1E-09 3.4
Cathepsin S 2.5E-12 1.5E-09 2.8
Cathepsin V 8 7E 13 6 5E 10 2 9 . - . - .
CCL28 8.8E-13 3.6E-10 2.6
CD109 2.1E-14 8.2E-10 4.6
CD23 2.0E-13 2.4E-10 3.1
CD30 6.9E-13 1.7E-09 3.4
CD30 Ligand 6.7E-13 1.2E-09 3.2
CD48 3.4E-13 8.0E-10 3.4
CD5L 2.1E-14 2.1E-10 4.0
CD70 1.1E-10 1.3E-08 2.1
CDK1/cyclin B 1.7E-12 3.0E-09 3.3
Chemerin 2.2E-13 4.4E-10 3.3
CHL1 1.9E-13 3.4E-08 5.3
Chordin-Like 1 2.3E-12 6.5E-10 2.5
CNTF 1.1E-13 5.7E-10 3.7
Coagulation Factor IX 2.4E-13 2.8E-09 4.1
Coagulation Factor IXab 1.4E-13 1.0E-09 3.9
Coagulation Factor V 9.0E-13 4.8E-10 2.7
Coagulation Factor VII 2.1E-12 2.1E-09 3.0
Coagulation Factor X 2.4E-11 1.4E-09 1.8
Coagulation Factor Xa 4.3E-13 2.0E-10 2.7
Coagulation Factor XI 3.8E-13 1.9E-09 3.7
complement factor H-related 5 5.2E-13 2.4E-10 2.7
contactin-1 7.5E-14 5.3E-10 3.9
Contactin-4 8.3E-13 1.2E-09 3.2
Cryptic 8.8E-13 1.4E-09 3.2
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CSK 5.3E-13 7.7E-10 3.2
CTACK 2.4E-12 1.2E-08 3.7
CTLA-4 6.9E-13 1.1E-09 3.2
CXCL16, soluble 1.1E-13 4.5E-10 3.6
Cyclophilin A 1.8E-13 9.7E-10 3.7
Cystatin C 5.4E-13 1.5E-08 4.4
Cystatin M 4.8E-13 7.7E-10 3.2
Cystatin SN 1.1E-12 6.4E-09 3.8
Cytochrome c 2.2E-12 3.1E-09 3.2
DAN 2.1E-12 4.8E-10 2.4
DPP2 3.6E-12 3.1E-09 2.9
ECM1 1.6E-13 2.0E-10 3.1
EG-VEGF 1.5E-12 8.8E-09 3.8
eIF-4H 8.6E-11 1.5E-08 2.2
Endostatin 1.3E-13 9.9E-10 3.9
Eotaxin 6.2E-11 2.5E-09 1.6
Eotaxin-2 1.0E-12 1.0E-09 3.0
EphA3 1.5E-12 1.1E-09 2.9
Ephrin-A5 4.6E-13 2.0E-09 3.6
Epo-R 8.2E-11 5.5E-09 1.8
ERBB1 3.8E-14 3.3E-10 3.9
ERBB2 1.7E-11 1.6E-08 3.0
ERBB3 2.9E-13 5.2E-10 3.2
ERBB4 1.0E-11 2.7E-09 2.4
ESAM 2.9E-14 3.4E-10 4.1
ETHE1 7.5E-13 1.8E-09 3.4
Factor B 9.4E-13 2.7E-08 4.5
Factor D 1 6E 12 9 5E 10 2 8 . - . - .
Factor H 6.8E-13 8.3E-09 4.1
Factor I 2.3E-14 4.5E-10 4.3
Fas ligand, soluble 6.8E-12 7.1E-09 3.0
FCγ2A 4.9E-13 1.1E-09 3.4
Ferritin 3.5E-11 1.0E-08 2.5
Fetuin B 6.9E-13 7.1E-11 2.0
FGF-16 1.6E-10 4.6E-08 2.5
FGF-18 1.0E-12 7.2E-10 2.8
FGF-19 5.7E-13 7.9E-10 3.1
FGF-20 7.9E-13 4.6E-10 2.8
FGF-4 4.4E-13 1.5E-09 3.5
FGF-6 6.1E-13 1.8E-09 3.5
FGF-7 2.6E-13 9.8E-10 3.6
FGF-9 2.0E-12 3.7E-09 3.3
Fibrinogen 4.2E-14 1.0E-09 4.4
Fibronectin 1.7E-12 2.4E-09 3.2
Ficolin-2 9.6E-12 1.6E-08 3.2
Fibronectin FN1.3 3.6E-14 1.3E-09 4.6
Fibronectin FN1.4 1.0E-12 4.2E-09 3.6
Fractalkine/CX3CL‐1 2.9E-12 5.6E-10 2.3
FSH 3.6E-12 2.6E-09 2.9
FSTL3 7.3E-14 3.5E-10 3.7
GAPDH 3.7E-13 1.1E-09 3.5
GCP-2 8.7E-13 7.5E-10 2.9
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GDF-11 1.2E-12 2.1E-10 2.2
gp130, soluble 9.4E-13 1.4E-09 3.2
Granulysin 2.1E-13 7.0E-10 3.5
Granzyme A 4.3E-14 3.9E-10 4.0
Group IIA phospholipase A2 6.5E-13 4.6E-10 2.9
Growth hormone receptor 4.8E-12 7.4E-09 3.2
Gro-α 6.5E-13 1.4E-09 3.3
Gro-γ 9.5E-13 1.1E-09 3.1
GSK-3 α 1.0E-06 1.0E-06 0.0
GSK-3 β 2.2E-12 1.3E-08 3.8
HAI-2 4.0E-13 6.3E-10 3.2
Haptoglobin, Mixed Type 1.9E-11 8.7E-08 3.7
HCC-1 9.9E-13 4.3E-09 3.6
HCC-4 1.1E-12 1.2E-09 3.0
Hemopexin 1.5E-12 1.0E-06 5.8
Heparin cofactor II 4.6E-13 3.0E-08 4.8
Hepcidin-25 1.3E-12 1.5E-09 3.1
HGF activator 5.9E-14 7.5E-11 3.1
HMG-1 1.4E-12 2.3E-09 3.2
HSP 60 4.8E-13 5.9E-10 3.1
HSP 70 9.6E-12 1.8E-10 1.3
HSP 90α 1.4E-12 1.2E-09 2.9
HSP 90β 3.5E-12 2.1E-09 2.8
iC3b 1.9E-13 9.0E-10 3.7
ICOS 1.1E-11 8.0E-09 2.9
IFN-γ 6.6E-13 4.2E-10 2.8
IgE 3.2E-13 2.3E-09 3.9
IGFBP 1 2 1E 14 7 2E 10 4 5- . - . - .
IGFBP-2 9.4E-13 2.4E-09 3.4
IGFBP-3 6.6E-12 1.9E-09 2.5
IGFBP-4 2.5E-13 2.0E-10 2.9
IGFBP-5 3.1E-13 3.6E-10 3.1
IGFBP-6 1.5E-13 1.1E-09 3.8
IGFBP-7 7.4E-14 3.1E-10 3.6
IGF-I 3.8E-13 7.4E-10 3.3
IGF-II receptor 4.6E-12 2.0E-09 2.6
IgM 8.2E-12 4.0E-09 2.7
IL-1 R4 4.1E-12 5.6E-10 2.1
IL-10 2.5E-12 1.5E-09 2.8
IL-11 6.3E-12 2.3E-08 3.6
IL-12 1.4E-10 6.7E-09 1.7
IL-13 9.9E-13 7.9E-10 2.9
IL-15 Rα 1.9E-13 2.4E-10 3.1
IL-16 9.4E-14 7.7E-11 2.9
IL-17 8.5E-13 3.3E-09 3.6
IL-17B 4.0E-13 3.3E-10 2.9
IL-18 BPa 1.4E-11 1.5E-09 2.0
IL-2 1.7E-13 1.3E-09 3.9
IL-2 sRγ 5.1E-12 5.4E-09 3.0
IL-4 2.7E-13 8.4E-10 3.5
IL-4 sR 2.4E-12 4.7E-09 3.3
IL-6 1.3E-12 1.0E-09 2.9
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IL-6 sRα 3.0E-13 8.0E-10 3.4
IL-8 7.3E-14 4.0E-10 3.7
ING1 1.8E-12 3.9E-09 3.3
Integrin α1β1 1.3E-11 7.9E-10 1.8
I-TAC 7.6E-13 5.8E-10 2.9
Kallikrein 4 1.6E-11 8.3E-09 2.7
Kallikrein 7 1.7E-12 5.6E-10 2.5
Kallikrein 8 8.2E-12 6.7E-09 2.9
Kallikrein 12 1.3E-12 6.1E-10 2.7
Kallistatin 7.4E-14 9.7E-10 4.1
Kininogen, HMW, Single Chain 8.4E-13 2.3E-10 2.4
Lactoferrin 1.4E-13 1.4E-09 4.0
LAG-1 1.6E-13 5.5E-10 3.6
Lamin-B1 7.8E-14 8.5E-10 4.0
LBP 2.6E-13 2.3E-10 2.9
LD78-β 7.2E-13 2.5E-09 3.5
LDH-H 1 8.4E-13 3.9E-09 3.7
Leptin 2.4E-12 8.6E-09 3.6
Leptin 8.3E-14 1.1E-09 4.1
Lipocalin 2 2.9E-13 1.6E-09 3.7
LRIG3 1.2E-13 5.2E-10 3.6
Luteinizing hormone 3.7E-13 4.5E-09 4.1
Lymphotactin 2.7E-13 2.7E-10 3.0
Lymphotoxin α1/β2 4.8E-13 1.7E-09 3.6
Lymphotoxin α2/β1 4.3E-12 1.1E-08 3.4
LYN A 6.7E-13 3.2E-09 3.7
LYVE-1 8.8E-13 7.0E-10 2.9
Macrophage mannose receptor 1.0E-11 6.6E-10 1.8
MAPK14 2.6E-12 4.4E-09 3.2
MAPK3 8.5E-13 3.4E-09 3.6
MAPKAPK2 1.9E-11 8.4E-09 2.6
MAPKAPK5 8.5E-11 8.4E-10 1.0
MCP-1 5.4E-13 5.2E-10 3.0
MCP-2 1.5E-12 9.8E-09 3.8
MCP-3 2.1E-12 1.0E-08 3.7
MCP-4 5.1E-12 6.1E-10 2.1
M-CSF R 5.1E-13 9.0E-10 3.2
MD-1 1.6E-12 3.6E-08 4.3
MDHC 2.9E-13 2.0E-09 3.8
Mesothelin 3.0E-12 1.3E-09 2.6
Mesothelin 9.8E-12 9.8E-09 3.0
MetAP 1 9.3E-13 2.1E-09 3.4
MIA 2.2E-13 1.7E-09 3.9
Midkine 4.0E-11 7.2E-09 2.3
MIP-1α 3.4E-12 5.8E-10 2.2
MIP-1β 6.8E-10 1.0E-06 3.2
MIP-4 1.3E-13 3.6E-10 3.4
MIP-5 2.4E-13 9.3E-10 3.6
MMP-2 4.6E-12 1.2E-09 2.4
MMP-3 3.1E-10 1.9E-08 1.8
MMP-7 2.5E-13 1.0E-09 3.6
MMP-8 1.7E-12 2.8E-09 3.2
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MMP-9 5.8E-13 3.8E-09 3.8
MMP-10 1.6E-12 1.8E-09 3.1
MPIF-1 1.2E-13 5.2E-10 3.7
MRC2 1.3E-13 3.3E-10 3.4
Myeloperoxidase 2.0E-13 1.3E-09 3.8
Myoglobin 2.4E-14 6.9E-10 4.5
Myosin regulatory light chain 2 1.2E-11 2.9E-09 2.4
NADPH-P450 Oxidoreductase 8.0E-13 9.7E-10 3.1
NAP-2 2.5E-14 2.3E-10 4.0
Netrin-4 3.1E-13 5.6E-10 3.3
Neurotrophin-3 1.9E-13 7.5E-10 3.6
Neurotrophin-5 6.7E-13 6.9E-10 3.0
Nidogen-2 1.4E-12 1.6E-08 4.1
Noggin 1.2E-11 4.4E-09 2.6
NRP1 1.0E-14 2.2E-10 4.3
OBCAM 4.8E-11 1.0E-06 4.3
RUNX-2 2.4E-13 7.2E-09 4.5
Osteonectin 1.0E-06 1.0E-06 0.0
Otubain-1 5.4E-12 7.1E-08 4.1
OX40 Ligand 4.0E-12 7.6E-10 2.3
PAI-1 2.8E-12 1.0E-06 5.6
PAPP-A 4.5E-13 6.1E-10 3.1
P-Cadherin 4.5E-12 2.6E-09 2.8
Protein C Inhibitor 1.1E-12 1.8E-09 3.2
PCNA 2.1E-12 1.8E-09 2.9
PDGF-BB 2.2E-13 6.5E-10 3.5
PF-4 6.2E-14 8.8E-10 4.2
PGRP S 4 4E 14 8 9E 10 4 3- . - . - .
PKC-ζ 2.7E-11 2.8E-08 3.0
Plasminogen 1.3E-12 6.3E-09 3.7
PLPP 3.0E-12 5.8E-09 3.3
Prekallikrein 3.5E-13 1.2E-09 3.5
Properdin 1.5E-12 2.2E-08 4.2
Protease nexin I 1.1E-12 3.7E-09 3.5
Proteasome subunit p40 5.3E-12 1.3E-08 3.4
Protein C 8.2E-13 2.0E-08 4.4
Protein S 1.4E-12 5.9E-10 2.6
Proteinase-3 3.6E-12 1.3E-09 2.6
Prothrombin 1.4E-12 1.0E-08 3.9
PSA 1.3E-12 1.6E-09 3.1
PSA-ACT 6.6E-14 5.4E-10 3.9
P-Selectin 1.0E-14 4.0E-10 4.6
pTEN 1.7E-12 1.6E-09 3.0
RANTES 7.0E-12 3.1E-09 2.7
RBP 9.1E-11 7.7E-08 2.9
Renin 2.6E-13 4.8E-10 3.3
resistin 1.4E-12 7.6E-10 2.7
RGM-B 1.9E-13 3.5E-10 3.3
ROR1 3.7E-13 2.4E-09 3.8
RPS6Kα3 4.1E-13 5.0E-10 3.1
S100A12 1.0E-06 1.0E-06 0.0
SAP 3.2E-13 1.8E-09 3.8
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SCF sR 3.1E-12 5.1E-10 2.2
sE-Selectin 1.1E-13 1.4E-10 3.1
ICAM-2, soluble 8.9E-11 8.9E-09 2.0
ICAM-3, soluble 2.9E-12 9.5E-09 3.5
Siglec-9 6.0E-14 1.8E-10 3.5
SLPI 9.3E-13 4.8E-09 3.7
sL-Selectin 2.0E-13 1.4E-09 3.8
Sonic Hedgehog 1.1E-13 2.3E-09 4.3
Sorting nexin 4 7.4E-13 2.5E-09 3.5
sTie-1 1.4E-12 4.2E-10 2.5
STK16 3.4E-12 7.5E-10 2.3
tau 1.2E-10 3.2E-08 2.4
Tenascin 6.7E-12 1.2E-09 2.3
TFPI 4.2E-14 6.4E-10 4.2
TGF-β1 2.4E-12 5.7E-09 3.4
TGF-β2 1.0E-12 3.4E-09 3.5
TGF-β3 9.6E-12 6.9E-09 2.9
Thrombin 6.5E-13 1.1E-09 3.2
Thrombospondin-4 1.6E-13 1.9E-09 4.1
Thyroid peroxidase 1.8E-13 1.2E-09 3.8
Thyroxine-Binding Globulin 1.4E-13 4.6E-10 3.5
TIMP-1 1.6E-13 2.0E-09 4.1
TIMP-2 6.4E-11 6.8E-08 3.0
TIMP-3 2.3E-13 1.6E-09 3.8
TNF sR-I 5.6E-13 1.2E-09 3.3
TNF sR-II 2.8E-12 2.1E-09 2.9
TNFSF18 8.7E-13 8.0E-10 3.0
tPA 7 4E 12 7 0E 10 2 0. - . - .
TRAIL R4 4.7E-12 3.3E-10 1.8
Transferrin 1.9E-12 4.7E-09 3.4
TrATPase 1.4E-13 1.3E-09 4.0
Troponin I 1.7E-11 4.2E-09 2.4
Troponin T 5.0E-11 3.4E-09 1.8
TSLP 1.0E-12 1.4E-09 3.1
UBC9 2.6E-14 3.8E-10 4.2
Ubiquitin+1 1.2E-12 1.7E-09 3.2
URB 3.8E-13 3.7E-10 3.0
VCAM-1 4.9E-12 1.1E-08 3.4
VEGF 9.4E-14 3.9E-09 4.6
VEGF sR2 3.8E-13 1.1E-09 3.5
VEGF sR3 8.3E-13 2.1E-09 3.4
vWF 1.1E-11 8.0E-10 1.9
WIF-1 1.2E-12 1.4E-09 3.1
WISP-1 2.9E-12 5.7E-10 2.3
X-Pro aminopeptidase 1 2.4E-12 3.7E-09 3.2
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Activin A 3.6E-12 1.1E-09 2.5 6.5E-13 7.5E-10 3.1
ADAMTS-4 1.0E-12 5.1E-10 2.7 1.1E-13 2.8E-10 3.4
CNTF 3.6E-13 7.1E-10 3.3 9.4E-14 2.2E-10 3.4
CTLA-4 3.1E-12 6.4E-09 3.3 1.9E-12 3.8E-09 3.3
EG-VEGF 1.8E-12 2.8E-09 3.2 2.4E-12 3.0E-09 3.1
Ephrin-A5 3.0E-12 1.6E-09 2.7 1.0E-12 5.2E-10 2.7
FGF-4 1.5E-11 1.7E-08 3.1 7.7E-12 1.1E-08 3.1
FGF-6 3.8E-12 2.9E-09 2.9 4.8E-12 9.9E-10 2.3
FGF-9 1.1E-10 9.0E-09 1.9 3.7E-11 6.3E-09 2.2
FGF-20 1.7E-12 6.5E-10 2.6 1.1E-12 2.7E-10 2.4
Granzyme A 5.2E-13 6.5E-10 3.1 1.6E-13 4.3E-10 3.4
HAI-2 5.5E-13 8.7E-10 3.2 3.3E-13 2.7E-10 2.9
IL-2 9.2E-13 1.4E-09 3.2 3.8E-13 6.2E-10 3.2
IL-4 6.3E-13 8.4E-10 3.1 1.1E-12 2.0E-10 2.2
IL-11 5.1E-12 1.0E-06 5.3 7.6E-12 5.1E-08 3.8
IL-17B 1.3E-12 1.8E-09 3.2 7.0E-12 5.5E-10 1.9
IL-4 sR 1.6E-11 5.9E-09 2.6 3.4E-12 6.5E-09 3.3
I-TAC 4.1E-12 1.4E-09 2.5 2.2E-12 8.8E-10 2.6
Lymphotoxin α1/β2 6.4E-12 2.8E-08 3.6 1.7E-12 7.5E-09 3.6
MCP-2 9.3E-12 5.5E-09 2.8 3.0E-12 2.2E-09 2.9
MCP-3 1.7E-11 7.7E-09 2.7 1.5E-11 6.6E-09 2.7
Neurotrophin-3 6.5E-13 8.4E-10 3.1 1.4E-12 4.9E-10 2.5
PSA 3.3E-11 1.0E-08 2.5 2.4E-12 1.7E-09 2.8
Sonic Hedgehog 1.5E-12 1.3E-09 2.9 1.4E-12 5.4E-10 2.6
TGF-β2 1.6E-12 1.0E-09 2.8 1.8E-12 7.4E-10 2.6
TNF sR-I 5.2E-12 1.0E-09 2.3 1.6E-12 7.3E-10 2.7
TNF sR-II 2.9E-12 6.5E-09 3.4 3.5E-12 1.3E-08 3.6
TNFSF18 2.3E-12 8.3E-10 2.6 9.1E-13 4.3E-10 2.7
Table 6. Limits of quantification for spiked proteins
Target Plasma Buffer
Concentration (M) (logRFU Fit)
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